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Circadian rhythms are self-autonomous endogenous clocks synchronized with the rotation 
of the Earth. With the Earth’s rotation and revolution on its axis, the internal clock undergoes 
oscillation in the period of ~24 hour and governs day to day activities in most organisms. In 
humans, it regulates the day to day physiological activities. Today’s modern lifestyle has an impact 
on health: shift work, jet lag, and irregular eating habits contribute to the misalignment of the 
endogenous circadian oscillator, thereby, increasing the risk of many metabolic disorders including 
diabetes, irregular blood pressure, sleep disorders, obesity, depression, and cancer. The primary 
goal of this research is to design and synthesize therapeutic circadian clock modulators to target 
clock-related dysfunctions.  
This dissertation focusses on designing a library of small molecules which can act on core 
circadian rhythm proteins. More specifically, the goal is to synthesize different analogs to target 
cryptochrome. Cryptochrome is an integral part of the mammalian core circadian system and 
regulates the process of gluconeogenesis, therefore it has been identified as a potential target for 
type II diabetes. A carbazole scaffold (KL001) was shown to bind at the active site of 




a library of the small molecules is synthesized and evaluated based on the structure-activity 
relationship of KL001. 
Just like mammals, most living organisms have developed an endogenous circadian clock. 
In the latter part of the dissertation, the focus shifts to study of the crucial circadian rhythm proteins 
of plants. In plants, Light Oxygen Voltage (LOV) domain proteins play an essential role in 
photoperiodic growth events. LOV domains employ small molecule chemistry to sense blue light 
in the environment and facilitate plants acclimating their surroundings. In Arabidopsis, the 
Zeitlupe (ZTL), flavin binding kelch repeat F-box1 (FKF1) and LOV Kelch protein-2 (LKP2) 
work in concert to measure the day length and to determine flowering time and regulate other 
circadian processes. Specifically, the focus will be to study the thermal kinetics of LKP2 protein 
of Arabidopsis thaliana. Furthermore, this study is extended to examine the thermal kinetics of 
LKP2 protein in an agriculturally important crop Brassica rapa. Finally, a crystal structure of the 
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CHAPTER 1  
CIRCADIAN RHYTHM: NEW AVENUES FOR THE DRUG DISCOVERY 
 
A famous dictum by Benjamin Franklin, “Early to bed, early to rise” is based on the theory 
that night is for sleeping while waking up should take place with the sunrise. Indeed, time plays a 
vital role in day to day life. A sudden shift in the routine can make us dysfunctional. Jet-lag is 
inevitable while traveling to the different time-zones. It is because of an internal circadian 
(biological) clock which dictates the daily physiological behaviors. This chapter provides a brief 
overview of the mammalian circadian rhythm, and asks a fundamental question; How does it 
govern our daily behavior? Are there any diseases associated? And if yes, then what efforts are 
being made to discover clock-based therapies to improve the human physiology. 
1.1 Introduction 
The key to life existing on the Earth lies in its ability to adapt to the environment. 
Organisms living in the different geographical conditions have adapted to distinct environment 
necessary for the survival. Essential to such adaptation and survival is the ability to synchronize 
daily events to the diurnal solar cycle. To adapt to such changes, most living organisms on the 
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Earth have evolved an internal biological clock that anticipates the fluctuation in day (light) and 
night (dark) pattern and optimizes the organisms’ physiology and behavior1. This intrinsically 
generated biological clock is known as a circadian rhythm.  
Circadian rhythms are self-autonomous endogenous clocks synchronized with the rotation 
of the Earth. Circadian clocks are defined by three requirements 1) They must demonstrate ~24-
hour period that is consistent with the Earth’s rotation and revolution on its axis and governs day 
to day activities in the organisms1-5. 2) The circadian period must be temperature independent 
(temperature compensated). 3) Despite the rhythm being synchronized with the Earth rotation, it 
must not depend on the sunlight (or any other exogenous cue) for its sustainability; indeed 
circadian rhythms still persist even in the dark hence they are endogenous free running rhythms of 
approximately 24-hours5-7.  
The internal biological clock anticipates dusk and dawn and prepares the organism to 
harness the maximum benefits of each aspect of the day/night cycle, while mitigating dangers 
associated with the damaging effects of the sun’s rays. Circadian rhythms are ubiquitous and are 
found both in prokaryotes and eukaryotes. Amongst prokaryotes, only cyanobacteria have been 
shown to have a robust circadian rhythm; which is likely associated with their photosynthetic 
abilities that necessitate temporal regulation of energy collection and use8,9. In eukaryotes such as 
plants, their sessile nature requires coordination of their growth and development with diurnal 
changes in environmental conditions. Hence, plants have developed an intricate array of several 
photoreceptors which work in a circadian fashion to assist plants in adjusting to the surroundings. 
These photoreceptors sense a broad spectrum of light which facilitates acclimation to the 
surrounding environment and regulates their growth and development10-11. Although mammals are 
not directly dependent on light for metabolic needs or growth and development, mammals retain 
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analogous circadian networks to temporally segregate metabolic pathways. Hence in mammals the 
circadian clock plays a vital role in governing daily metabolic activities like a sleep-wake cycle, 
hormone secretion and diverse aspects of human physiology. 
Hence, it is not wrong to say circadian rhythm is a “timekeeping” mechanism present in 
nearly all the organisms residing on the Earth. Therefore, it is imperative to study the molecular 
basis of circadian clocks to provide a deeper insight into the nature of biological timekeeping and 
the intricate mechanisms necessary to coordinate and synchronize such a clock with environmental 
factors. In this chapter, we go in depth to understand how the clock works through the 
implementation of a negative feed-back loop. Further, we will develop a brief history of the 
circadian rhythm research. Finally, this chapter will delve into the specific biochemical pathways 
that maintain mammalian circadian rhythm and discuss how the core circadian protein 
cryptochrome plays a vital role in human disease including in regulating diabetes.  
1.2 Characteristic and Molecular basis of the circadian clock 
The core component of a basic circadian clock consists of an input pathway, which 
perceives the stimulus from the environment and transmits the environmental signal to a central 
oscillator. The central oscillator, in turn, entrains the signal and maintains ~24-hour endogenous 
rhythm that modulates diurnal regulation of desired outputs such as gene expression. Notably, 
some output feedback into the core oscillator rhythmically suppresses gene expression. As a result, 
the next cycle starts, and the process continues. This process is called feedback inhibition and is a 




Figure 1: An abstract view of circadian rhythm: The input signal activates the pacemaker of 
the biological clock, which in turn, drives the expression in a rhythmic fashion 
All circadian processes follow the same pathway in all the organisms residing on the Earth, 
e.g. plants, fungi and animals. However, the number of proteins participating differs, depending 
upon the complexity of an organism. For these reasons, much of the initial circadian rhythm 
research focused on understanding how the central oscillator is able to maintain a temperature 
compensated 24-hour period through regulation of a negative feedback loop.   
 
1.2.1 The feedback loop 
 
“What goes up, must come down, spinning wheel got to go around.” 
At the core molecular level, circadian rhythm involves successive gene expression and 
repression through a transcription and translation feedback loop (TTFL). The process is well-
coordinated and orchestrated like a musical rhythm. Just like a wall clock, the feedback loop 
consists of two elements: a positive limb (or element) which drives the expression of all genes 
under control of the circadian clock and the negative limb (or element) that inhibits gene 
expression leading the path for a new cycle to begin. Importantly, the TTFL and feedback loops 
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do not operate in isolation. Coincident with transcription/translation numerous post translational 
regulation events modulate the stability and function of key clock proteins. For instance, a set of 
ubiquitin ligase protein maintains the periodicity by subsequently degrading the repressor proteins, 
such that a new cycle can get started with the 24 hours periodicity and thereby improving the 
robustness of the circadian network and facilitating adaptation in the presence of diverse 
environmental signals. By this process, the internal clock is synchronized with environmental 
signals allowing an organism to both maintain a 24-hour period (TTFL), but also adapt to 
environmental change or pressures through peripheral loops that involve post-translational 
pathways. Without this complicated interplay between the core TTFL and peripheral loops, we 
would not be able to adapt to different time zones and overcome jet lag14-17. 
 
Figure 2: General mechanism of autoregulatory feedback inhibition in the basic circadian 
clock: The positive element drives the expression of the negative element, which in-turn inhibits 





1.2.2 Important clock parameters  
 
The autoregulatory feedback inhibition (circadian rhythm) of gene regulation can be tested 
in a laboratory. Experiments are typically done by measuring gene expression, behavior cues or 
epigenetic modification over a multiple-day time course. These time courses are conducted on 
samples after they have been synchronized (entrained) by the environmental stimuli such as: 
alternating light and dark cycle or drug or small molecule introduction. In conducting such studies, 
there are specific terms used during these experimental approaches which are unique to the field. 
We explain these terms below:  
Zeitgeber time (ZT): is the German term which means “time giver.” It is a standard notation of 24-
hour phase, where ZT = 0 means dawn (or beginning of the experiment) and ZT = 12 is termed as 
the beginning of the dark phase or night.  
Period: Period is the time taken to finish one cycle. It can be measured as the distance between 
two consecutive peaks or troughs (Fig 3). To be considered circadian, the period must remain 
approximately 24-hours regardless of temperature. 
Phase: Phase is the time of day at which a particular event occurs. For instance, if an element 
within the circadian rhythm demonstrates a peak at 12 hours after ZT = 0 (dawn), then the phase 
will be 12 hours10. 




Figure 3: Important clock parameters: Period is the time taken to complete one cycle. Phase is 
the time at a particular event. Amplitude is half of the distance between a peak and trough 
1.3 Discovery of circadian rhythm to chronotherapy: Historical perspective 
Circadian rhythms were said to be first observed by the Greek geographer Androsthenes at 
the time of Alexander the Great in 4th century B.C when he noticed daily leaf movements of the 
tamarind tree, Tamarindus indicus on the islands of Tylos (now Bahrein) in the Persian Gulf. 
Despite such observations, it was another two millennia until the first experimental studies on 
circadian rhythms were conducted. They were conducted by the French astronomer Jean-Jacques 
d’Ortous de Mairan, who reported leaf movements of the sensitive Mimosa pudica plant 
(commonly known as “touch me not” plant) were persistent even in the constant darkness, which 
led him to conclude the rhythm to be endogenous and self-sustaining16. He later extended his 
research to the human patients with sleep defects. After that, in 1729 he published the first paper 
in circadian rhythm research. These experiments were not without controversy, and numerous 
researchers tried to debunk or better understand how non-human species could measure time. 
Research on circadian rhythms became more formalized in the 20th century. In 1950s Franz 
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Halberg coined the word “circadian” from the Latin word circa diem (about a day)1,19. Over the 
last 100 years, identification of the molecular components of circadian clocks has attracted the 
attention of both biochemists and chemists, who aimed to identify fundamental chemical and 
biochemical components necessary to maintain biological clocks. These efforts have led to 
substantial research aimed at unraveling how circadian rhythms dictate growth and development 
in plants, to aid in crop production, and regulation of diverse aspects of human physiology as it 
relates to disease phenotypes. Today it is a fast-growing field in biomedical research. Delightfully, 
last year in 2017, the Nobel prize in physiology or medicine was awarded to Jeffery C. Hall, 
Michael Rosbash and Michael W. Young for their discoveries of the molecular mechanism that 
controls circadian rhythms. 
1.4 Mammalian circadian rhythm 
In mammals, the circadian clock plays pivotal roles in governing physiological and 
metabolic processes like the sleep-wake cycle, hormone secretion, bowel movement, body 
temperature, heart rate, and numerous others14, 15. Sudden changes in environmental inputs or 
behavior thus leads to misalignment between the environment and physiological processes. 
Diverse studies indicate that misalignment of the clock contributes to diverse disease phenotypes 
and disorders. Importantly, circadian rhythms maintain the ability to reset the clock to re-entrain 
endogenous rhythms in response to environmental inputs. For instance, traveling in another part 
of the globe can lead to jet lag as the sleep-wake cycle gets disturbed. After some period, however, 
we will naturally adapt to the new environment in response to metabolic cues (feeding) and 
environmental light input. That is why one of the primary mechanisms recommended to deal with 
the jet lag is to eat according the time of the day, and to look at the morning sun at the destination 
and sleep according to the local day-night cycle.  
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The circadian system of the mammals includes the input pathways, the central clock and, 
the output. Light is the principal input; however, many output activities like food, temperature, 
and physical activity reciprocally regulate the clock10, 13.  
 
Figure 4: An abstract view of the mammalian circadian rhythm: The suprachiasmatic nucleus 
(SCN) acts as a central oscillator. Light, the primary source of input activates the SCN, which in 
turn relays the message to the peripheral organs. The clock also receives reciprocal effect from the 
output such as food intake, temperature, and physical activity. 
Light is the primary synchronizer of the biological clock. Light enters through the eyes, 
gets perceived by the photoreceptor cells retinal ganglion located in the retina which then relays 
the signal down through the optic nerve into the suprachiasmatic nucleus located in the 
hypothalamus. The suprachiasmatic nucleus is the master regulator, also known as the pacemaker, 
of the circadian clock in mammals20,22. Within each nucleus, there are about 20,000 neurons 
capable of generating circadian rhythm in a self-autonomous manner. Subsequently, neural and 
hormonal signals from the SCN entrains peripheral organs and tissues, synchronizing clocks in 
nearly all cell types to the daily light-dark cycle. These peripheral organs and tissues then behave 
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in a circadian fashion and participate in hormone secretion or other metabolic processes to maintain 
homeostasis14, 16,18, 21-25. 
 
Figure 5: A model of mammalian circadian rhythm system: Light activates the retinal ganglion 
cells in eyes, the signal gets relayed to the suprachiasmatic nucleus (SCN), which acts as a 
pacemaker of the circadian rhythm. The SCN then entrains signals to activate peripheral organs 
via neural and endocrine pathways.  
Because of the biological clock, the human body has a natural tendency to maintain 
homeostasis. Disruption or misalignment of this behavior due to genetic manipulation or 
environmental factors can lead to many physiological defects, such as sleep disorders, 
cardiovascular disease, diabetes, obesity, cancer and other metabolic disorders. Consequently, 
understanding the biochemical mechanisms dictating circadian clock function can open new 
avenues in treating metabolic diseases or disorders at the genomic level and could have a 
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substantial impact on human health13. This has paved the path of chronobiology or chronotherapy, 
which means treating disorders by modulating the natural rhythm. 
1.5 Molecular architecture of the mammalian circadian clock 
In mammals, the canonical auto-regulatory transcription-translation feedback loop (TTFL) 
consists of four core components: two transcription activators: CLOCK (Circadian Locomotor 
output cycles kaput) and BMAL1 (Brain and Muscle Aryl-hydrocarbon receptor nuclear 
translocator Like protein-1), and the transcriptional repressors, Periods (PERs) and Cryptochromes 
(CRYs). In the core clock network transcription activators CLOCK and BMAL1 act as a positive 
arm, whereas two of their target genes CRYs and PERs act as the repressor proteins to form the 
negative limb of the TTFL. (Fig. 6 and 7) 
Mechanistically, this is achieved by the transcription activator proteins CLOCK and 
BMAL1, which heterodimerize to dictate the expression of clock-controlled genes (ccgs) via E-
box promoter elements. Upon accumulation, CRY and PER, in turn, heterodimerize in the 
cytoplasm, translocate back to the nucleus to restrict their transcription by retarding CLOCK: 
BMAL1 transcription. Currently, the mechanism by which CRY and PER alter CLOCK:BMAL1 
expression is poorly understood, but it is believed to involve a large (megadalton) protein complex 
recruiting numerous chromatin remodeling agents and transcriptional repressors to the promoter 
elements. In conjunction with CLOCK:BMAL1 repression, CRY and PER are targeted for 
degradation by ubiquitin-dependent proteolysis pathways. Degradation of CRY and PER relieves 
the repression on CLOCK and BMAL1 gets relieved, and the process continues again with 
approximately 24-hour periodicity1-5,15-18,21.  
The ubiquitination mediated proteasomal degradation pathway in the negative feedback 
loop plays a crucial role in maintaining a robust circadian oscillator. The ubiquitination process 
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involves targeting protein for the 26S proteasomal degradation. At the post-transcriptional level, 
SCF (Skp1-Cullin-F-box protein) complexes such as b-TrCP (beta-transducin repeat containing 
E3 ubiquitin protein ligase) and FBXL3 (F-box and leucine-rich repeat protein 3) regulate the 
stability of PER and CRY respectively and maintain the circadian rhythmicity24,25. More 
specifically, kinases like casein kinase (CK1)26 and AMPK (adenosine monophosphate-activated 
protein kinase) phosphorylate PER and CRY respectively. The respective F-box proteins then act 
upon the phosphorylated proteins and form an E3 ubiquitin ligase complex. The tagged protein, 
subsequently, undergoes degradation by the 26S proteasome complex. Another homolog F-box 
protein of FBXL3, FBXL21 antagonizes the CRY degradation in the nucleus; thereby facilitates 
the CRY turnover rate in the cytoplasm17, 21,28,31. Such competitive processes are common in 
circadian networks and are believed to contribute to the robustness of the circadian oscillator.  
Besides the core circadian oscillator, numerous feedback loops also participate in 
modulating circadian function. One such secondary stabilization loop consists of nuclear hormone 
receptors REV-ERB a/b and the antagonist-receptor ROR a/b/g29,30. Both REV-ERBs and ROR 
(retinoic acid receptor related orphan receptors) work antagonistically and dictate the expression 
of the core transcription factor BMAL131, 32. CLOCK/BMAL1 heterodimer, in turn, activates the 
ROR and Rev-erb gene expression 21,33,34. In this manner, peripheral loops can integrate diverse 
pathways such as stress response, metabolism and cell-cycle repair into the core clock network 
through secondary feedback loops. These secondary loops both facilitate cross-talk to diverse 





Figure 6: The molecular architecture of mammalian circadian rhythm: An autoregulatory 
circadian feedback loop involves: the core loop consisting of the activators: CLOCK/BMAL1 and 
the repressors: CRYs and PERs. The stabilizing loop involves Rev-erbα and ROR that regulates the 
expression of BMAL1. CLOCK/BMAL1 heterodimer also regulates the downstream clock-
controlled genes (ccg). The stability of CRY and PER is regulated by the F-box proteins FBXL3 
and b-TrCP respectively. The kinases, casein kinase 1(CK1) and AMPK phosphorylates PER and 
CRY respectively to promote the ubiquitination via their respective F-Box proteins. The F-box 
proteins tag PER and CRY for the degradation by the 26S proteasome complex. (Adapted from 
Ref:33) 
Importantly, all peripheral tissues and organs follow the same mechanism to couple 
physiological and metabolic pathways to the circadian clock. All the core proteins involved in the 
TTFL are crucial for the proper metabolic functioning. Indeed, several studies have shown 




To summarize, the circadian rhythm in mammals is generated by a set of hierarchal 
interlocking genes that undergo self-autonomous transcription/translation feedback loops, 
resulting in cascades of gene expression. To promote understanding, Fig 7 shows the simplified 
version of the circadian loop. 
 
Figure 7: Overall view of the circadian rhythm in mammals: Light activates the 
suprachiasmatic nucleus located in the brain. The SCN then acts as a pacemaker of the circadian 
rhythms and relays the signal down to the peripheral organs though neural or hormonal signals. 
On the molecular level, the core circadian clock involves CLOCK and BMAL heterodimerize 
rhythmically to drive the expression of CRY and PER, which in turn repress the expression of 
CLOCK: BMAL through feedback inhibition.  
1.6 Structures of the core circadian rhythm proteins 
The circadian clock genes in mammals show rhythmic expression not only in the 
suprachiasmatic nucleus (SCN) which is the pacemaker of the circadian clock generation but also 
in the peripheral organs15. The core components of circadian clocks involve the hierarchy of genes 
working in a rhythmic fashion. Central to this function are numerous competing and/or cooperative 
protein:protein interaction networks that are modulated by post-translational modifications. To 
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unravel the mechanism by which these protein:protein interaction networks modulate clock 
function, and to delineate their signaling mechanisms, significant effort has been placed in 
obtaining high-resolution structures and/or low resolution biophysical information on clock 
proteins and functional protein complexes21,28. Recently, the high-resolution crystal structures of 
several critical interacting proteins and proteins bound to the small molecule have become 
available. These include a crystal structure of the CLOCK: BMAL1 complex35, the crystal 
structures of isolated domains of all three PER proteins36,37, and crystal structures of multiple 
functional forms of CRY proteins38-41. Table 1 summarizes the crystal structures of core clock 
components known so far along with their PDB codes and the ligand bound.  
      Table 1: Crystal structure known for the core circadian proteins (adapted from Ref:28) 
 
These crystal structures provide a snapshot of a protein/interacting proteins and hence 
reflect better insight into protein function and signaling mechanisms. For instance, the crystal 
structure of CRY complexed with FBXL3 has revealed the mechanism by which the C-terminal 
tail of the FBXL3 interacts with the CRY to initiate the degradation process40. In combination with 
a crystal structure of the mCRY with its small molecule stabilizer (KL001), researchers were able 
to delineate the mechanism by which small molecules can modulate clock function by attenuating 
Protein Domain Ligand PDB-ID 
mCLOCK: mBMAL1 bHLH DNA 4H1035 
mPER1 PAS AB  4DJ236 
mPER2 PAS AB  3GDI37 
mPER3 PAS AB  4DJ337 
mCry apo form PHR-CC  4K0R38 
FAD bound mCRY PHR-CC FAD 4I6G40 
mCRY with FBXL3 PHR-CC FBXL3 4I6J40 
mCRY with KL001 PHR-CC KL001 4MLP41 
CRY2 in complex with per PHR-CC  4CT039 
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the stability of CRY proteins. Namely, the carbazole scaffold mimics the isoalloxazine ring of the 
FAD to bind to the vacant FAD binding cleft in mammalian CRYs. In doing so, KL001 
impersonates the FBXL3 tail thereby competitively binds to the CRY:FBXL3 interaction site and 
delays the degradation process41. Thus, obtaining a high-resolution crystal structure not only assist 
in understanding the signaling mechanism but also aid in designing small therapeutic 
molecules8,9,21,44. 
1.7 Resetting the clock: Chemical chronotherapy 
Today’s modern lifestyle is impacting health and that ultimately is contributing to the 
misalignment of the circadian oscillator with our normal day-night cycle. Shift work, frequent 
travels to different time zones, and irregular eating habits contribute to misalignment of the internal 
clock with the normal day night-cycle and are increasing the risk of many physiological disorders 
like diabetes, sleep disorders, obesity, depression, and cancer6,23,50,51. 
Recent research identifies significant health benefits that result from robust circadian 
rhythms. As a result, medical researchers now focus on how circadian rhythms may modulate our 
health or treatment practices. Initially, chronotherapy focused on identifying whether there were 
specific times of day where drug or stimulus administration achieved the optimal therapeutic index 
and pharmacokinetic profile. Interestingly, such approaches clearly indicated time-of-day specific 
administration of elements as simple as blue (morning) and red (evening) light positively impacted 
patients suffering from insomnia or depression. As a matter of fact, time-of-day specific light 
treatments have been used as a drug-free remedy for the seasonal affective disorder (SAD)42,43. 
Furthermore, extension of such time-of-day specific approaches to therapeutic intervention has 
had significant impact on cancer patients, as they showed fewer side effects when the anti-cancer 
drug gemcitabine was administered at 9 AM daily instead of 3 PM44. Delightfully, identification 
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of the molecular architecture of the circadian rhythm proteins and their role in physiology has 
emerged a new era in the field of chronobiology44,45,46. In particular, specific focus has been on 
targeting core clock proteins directly, to deal with the negative consequences of misalignment 
between endogenous circadian rhythms and the diurnal cycle.  
Of late, small molecules are being exploited to manipulate the misaligned clock to prevent 
or alleviate the clock related diseased conditions. Additionally, small synthetic drug-like molecules 
bestow great potential to not only understand the function of the molecular clock system but also 
can be used to target the diseases associated with the clock dysfunction. The approach anticipates 
modulating the endogenous biological rhythm which can potentially “reset the clock” and 
hopefully can treat physiological or metabolic pathologies13,34,45. 
1.7.1 Circadian rhythm and drug intervention 
 
Different clock elements (discussed earlier in the section 1.5) have been shown to impart 
pathological disorders in mutant mice; implying, each component of the mammalian circadian 
clock system has a crucial function. For instance, CLOCK mutant mice were found to be 
hyperglycemic and obese whereas BMAL1 deficit mice showed decreased body weight and 
infertile6,16,20,32. Additional physiological defects resulting from clock genotypes are outlined in 





 Table 2: Summary of the diseases associated with the mutation of different core clock elements 
 
 
1.7.2 Identification of the synthetic clock modulators 
  
The circadian rhythm is highly pliable and can reset by external cues such as environmental 
change or metabolism; therefore, small molecules can be used to modulate the rhythm13,44-48. The 
purpose of drug discovery is to target either the input pathway or the feedback loop. Moreover, the 
primary goal is to target the core clock component instead of components far away from the central 
oscillator to avoid pleiotropic effects13. Incidentally, modern research has determined that all core 
proteins are druggable, and most of them have an endogenous ligand that drives their actions. For 
instance, REV-ERBa/ b employs a Heme cofactor, while RORa has been found to be regulated 
by cholesterol. Alternatively, important dinucleotides such as flavin adenine dinucleotide (FAD) 
and nicotinamide adenine dinucleotide (NAD) have been found to be signaling molecules for core 
circadian proteins like cryptochrome (in plants and insects) and BMAL148 respectively. In plants 
Mutant Physiological Disorder 
CLOCK Altered sleep pattern, hyperglycemia, diet 
induced obesity6,49 
BMAL1 Decreased body weight, infertility, premature 
death 16 
CRY I and II Alterations in liver regeneration, 
hyperglycemic conditions due to 
gluconeogenesis, altered sleep pattern, glucose 
intolerance8,50,51,52  
PER 1 and 2 Cancer development, improper cell division, 
abnormal apoptosis16  
REV ERB Dyslipidemia53 
CK1e/d Familial advanced sleep phase syndrome43,54  
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and insects, FAD governs the signaling mechanism of the CRY in a light-dependent manner. 
Despite retaining the FAD binding pocket, vertebrate CRYs are not photo regulated and do not 
bind FAD, but the binding pocket can be targeted to regulate clock function (e.g. KL001)48. 
Additionally, NAD regulates the activity of the CLOCK BMAL1 complex through a feedback 
loop involving SIRT1. Fig 8 shows the structures of the endogenous ligand of the core clock 
proteins. 
 
Figure 8: Endogenous ligands of the important circadian proteins. The structure of the ligands 


































































Assuming that most of the clock components are under control of endogenous ligands, that 
provides the lead to synthesize small drug-like molecules which can mimic the natural metabolite 
and modulate the clock as well as treat diseases associated with the clock dysfunction. In particular 
small-molecule screens have been assayed for their effect on circadian period and amplitude, 
yielding identification of a host of clock-affecting small molecules targeting nearly all components 
of the core and peripheral clock elements. In addition to testing small molecule libraries, efforts 
are also being made to test FDA approved drugs that might target circadian proteins to reduce the 
cost of identifying new bioactive molecules. For instance, Tamai et al. tested approximately1000 
molecules from the FDA approved library and found approximately 5% of them had period 
shortening abilities56.  
Nevertheless, the burgeoning circadian modulator research has identified several new small 
molecules which act on different clock proteins. Fig 9 shows some of the potent circadian clock 
modulators synthesized and the part of the cycle/protein they act on. Additionally, Table 3 




Figure 9: Circadian clock modulators: Some of the circadian clock modulators and their protein 









Table 3: Summary of the small molecules synthesized to mimic the endogenous ligand of the core     
circadian proteins and their therapeutic actions 
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However, for the purpose of this dissertation, we will narrow down our focus to the core 
clock component CRY. Henceforth, we will discuss cryptochrome and its function in mammalian 
circadian rhythm, followed by drug intervention.   
1.8 Cryptochrome as a target of drug discovery 
1.8.1 Cryptochrome 
 
Cryptochromes were first identified in Arabidopsis thaliana and were named 
“cryptochrome” as their function was “cryptic” and for their widespread abundance in cryptogamic 
plants61-63. They exhibit sequence homology with DNA photolyase and hence belong to the CPF 
family (Cryptochrome photolyase family). The founding member of the family, photolyase is 
found in most organisms, where it functions as a light-driven enzyme that repairs UV damaged 
DNA64. Initially, widespread efforts failed to identify a photolyase in placental mammals, the 
closest homologs were identified as the Cryptochrome family. Domain structures of CRYs 
demonstrates that it retains a photolyase homology region characteristic of the CPF family. In 
addition, it has a disordered cryptochrome C-terminal (CCT) or extension (CCE) 
equivalently26,40,61,64,65. Despite high sequence homology, cryptochromes do not participate in 
DNA repair activity. Instead, they sense blue light in plants and contribute to growth and 
development, whereas in mammals they work in a light-independent manner and are the part of 




Figure 10: Domain architecture of the mammalian cryptochrome: Mammalian cryptochrome 
has a photolyase homology region along with a disordered C-terminal extension. 
The animal cryptochrome was first discovered as a photolyase like protein with no DNA 
repair activity in animals in 199566. The animal cryptochromes can be classified as CRY type I 
(CRY1) and CRY type II (CRY2), which are differentiated based on the presence and function of 
the FAD cofactor. While CRY1 proteins readily bind FAD and demonstrate blue light sensitivity 
to participate in light-activated circadian behavior in Drosophila, CRY2 proteins are currently 
believed to not bind FAD, but rather work in a light-independent manner in the mammalian 
circadian clock66. As discussed above, CRY along with period (PER) acts as a repressor of BMAL1 
and CLOCK. However, the mechanism by which it interacts with the complex is still elusive. As 
noted, unlike other cryptochromes, which have been crystallized and the role of cofactor the flavin 
adenine dinucleotide (FAD) in the signaling mechanisms are well known67,68, the mammalian 
cryptochrome weakly binds FAD with an open cofactor pocket and is believed to function in an 
FAD independent manner, where the FAD binding pocket has been co-opted to function as a 
protein:protein interaction site21,28,40,72. Moreover, recent biochemical studies have shown CRY 
regulates gluconeogenesis in mammals and therefore, could be a potential target for treating type 
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II diabetes 51,69-71. Hence the development of a small molecule that can mimic FAD might not only 
assist in understanding the signaling mechanisms of CRY but could also can set the stage for drug 
development55.  
1.8.2 Cryptochrome regulation of gluconeogenesis  
 
Gluconeogenesis: 
Gluconeogenesis, by definition, is “generation of glucose from non-carbohydrate 
precursors.” It is a metabolic process and is stimulated by glucagon and epinephrine in the liver. 
It is the process by which human body maintains optimal blood glucose level and hence glucose 
homeostasis. During the daytime, or when the body is in its feeding cycle, glucose requirements 
are fulfilled by food intake. The body utilizes the required amount of sugar and converts the rest 
for storage in the form of fat. At night, or during fasting cycles, the pancreas secretes glucagon to 
activate hepatic gluconeogenesis process and avoid hypoglycemic condition55,70. 
 
Figure 11: Glucose homeostasis: During daytime or the feeding cycle, the body utilizes glucose 
supplied by food-intake and stores excess glucose in muscles and adipose tissue. On the contrary, 
at night time or the fasting cycle, glucagon gets secreted by the pancreas which activates the G-
protein coupled receptors and thereby cAMP. The cAMP ultimately phosphorylates CREB, and 
that activates gluconeogenic genes to secrete glucose from non-carbohydrate sources.  
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At the fasting cycle, glucagon secreted by the pancreas binds to the G-protein coupled 
receptor (GPCR) or glucagon receptors in hepatocytes (liver cells), which in turn triggers 
intracellular cyclic AMP (cAMP) resulting in CREB (cAMP response element binding) 
phosphorylation and subsequent expression of gluconeogenic genes like pyruvate kinase (Pck1) 
and glucose-6-phosphatase (G6pc). Importantly, gluconeogenic genes are expressed rhythmically 
and are controlled in a circadian fashion51,69-71.  
“High Glucose, No CRY”  
Recent studies by Zhang et al. demonstrated that cryptochrome controls gluconeogenesis 
process rhythmically. By luciferase in-vivo imaging technique they demonstrated that when CRY 
is active it inhibits cyclic AMP production and hence modulates gluconeogenesis at the genomic 
level 51,69-71.     
To summarize, cryptochrome forms a “gate” for gluconeogenesis in humans. In the 
morning time (or during the active feeding cycle), high CRY levels inhibit the gluconeogenesis 
process. On the contrary, during nighttime (or fasting cycle), CRY levels are low, and 





Figure 12: The cryptochrome acts as a gate for the gluconeogenesis process: Cryptochrome is 
active during the feeding cycle and inhibits glucagon-stimulated cAMP production which further 
prohibits the gluconeogenesis process. At the nighttime or at the fasting cycle, cryptochrome 
becomes inactive and glucagon induces the gluconeogenesis process to take place.  
1.8.3 Gluconeogenesis and Diabetes  
 
Diabetes mellitus type 2 is a metabolic disorder characterized by hyperglycemia or high 
blood sugars as cells become insulin-insensitive and fail to take up glucose which leads to 
dysregulation of glucose homeostasis. Diabetes II is the seventh leading cause of death in the 
United States. According to the US department of health and human services (2014), 
approximately 29.1 million Americans have diabetes with 1.7 million diagnosed every year70.  
Hyperglycemic conditions can cause several other diseases such as heart failure, obesity, 
strokes, kidney failure, and blindness. Moreover, gluconeogenesis is a regular metabolic process 
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which can lead to persistent hyperglycemic conditions in diabetic patient. Therefore, designing 
drugs which can target the hepatic gluconeogenesis process can facilitate in maintenance of 
optimal blood glucose levels73.  
As discussed earlier, recent research affirmed that cryptochrome when rhythmically 
expressed could inhibit the hepatic gluconeogenesis process. As such, cryptochrome was identified 
as a suitable drug target. Specifically, if cryptochrome levels are modulated or stabilized through 
a small molecule, then production of glucose by the process of gluconeogenesis can be suppressed. 
1.9 Cryptochrome modulator 
Cryptochrome is a core protein of the mammalian circadian rhythm that controls many 
physiological processes. As discussed earlier in the chapter, gluconeogenesis is modulated when 
cryptochrome is expressed. The big vision is to synthesize a small molecule which can stabilize or 
delay the degradation process of the cryptochrome. A stabilized cryptochrome can delay the 
gluconeogenesis for long and thereby help to alleviate hyperglycemic conditions in the diabetic 
patient48,57,58. 
 
Figure 13: Cryptochrome as a drug discovery target: A stabilized cryptochrome would restrict 
gluconeogenesis process for a longer period which potentially aids in lowering the blood glucose 
level and hence would help the diabetic patient in maintaining an optimal level of glucose. 
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Hence, the goal of the small molecule intervention is to synthesize a scaffold which can 
stabilize the cryptochrome and delay its degradation process. However, to date, its action in the 
regulation of cryptochrome (CRY) is elusive. Notably, vertebrate CRYs (type 2 CRYs) are unique 
in that they do not bind FAD, but rather employ the FAD binding site to interact with FBXL3, to 
target the protein for degradation. Thus, it is plausible that identification of a small-molecule that 
could compete at the FAD binding site would allow both interrogation of the signaling pathway of 
CRYs, but also result in CRY stabilization through competition with FBXL3. Furthermore, such 
molecules could unravel cryptochrome’s mode of action in the sleep-wake cycle, diabetes and 
other related metabolic disorders. Remarkably, high throughput analysis of the effect of ~60,000 
compounds on the circadian period in human osteosarcoma U2OS cell lines harboring Bmal-dLuc 
reporter showed three carbazole-containing scaffolds with dose-dependent period lengthening 
effects, consistent with what would be expected for a CRY-stabilizer. Among the three, KL001 
showed pronounced period lengthening effect in a dose-dependent manner. KL001’s action in the 
modulation of the clock could suggest potential therapeutic effect towards diabetes and other 














KL001 was found to be first of a kind of small-molecule that could stabilize CRY. 
Incidentally, KL001 indeed competitively bound to the SCFFBXL3 binding site (an F-box protein 
which tags cryptochrome for proteasomal degradation), hence prevents its ubiquitination process 
and stabilizes cryptochrome. Cryptochrome stabilization by KL001 ultimately lengthens the 
overall period of the cryptochrome, enabling the therapeutic potential40,41,57. 
 
Figure 15: KL001 mode of action. KL001 competitively binds at the FBXL3 binding site of the 
flavin and prevents it from degradation, which in turn lengthens the period.  
Previous studies have shown that CRY2-FBXL3 complex involves insertion of the C-
terminal tail of FBXL3 into the FAD binding pocket of the cryptochrome21,40,41, hence 
competitively binding of KL001 in the FBXL3 pocket was postulated as the mechanism of KL001 
induced stabilization of CRY. The postulation was further confirmed by the crystal structure of 
CRY2 PHR bound by KL001. Nangle et al. compared the crystal structure with that of FBXL3 
bound CRY and confirmed that KL001 and FBXL3 compete for the same FAD binding pocket. 
Moreover, high resolution (1.94 Å) structures have unraveled the binding ability of the KL001 in 
the FAD-binding pocket, giving better insights for drug discovery41.  
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1.10 Research Objective 
This dissertation mainly focuses on designing the small molecules to target the core 
circadian protein cryptochrome.  In this work, we have deeply investigated the crystal structure of 
the cryptochrome in complex with KL001 using modeling software such as Coot and Pymol. 
Insights gained from the structure-activity relationship, we have designed the “Zoltowski Library” 
consisting of 10 different small molecules. In the initial part of the research, we modified the 
scaffold and replaced the carbazole with Delta-carbolines, Pinoline, and Quinoxaline derivative to 
target the core scaffold for improved binding to the CRY FAD binding site.  
Motivated by our previous results, we further investigated the crystal structure of KL001 
bound cryptochrome and designed numerous side chains for better recognition and binding. 
Furthermore, we also focused on changing the linker region. All resulting compounds were tested 
for activity by interrogating their effect on circadian period in U2OS cells harboring the BMAL1-
dLuc reporter. Although the research is in the primary stages of the circadian modulators 
development, we can still get better insights to proceed with the synthesis of more compounds. 
In the latter part of this dissertation, we will steer the focus to study about LOV domain 
proteins of plant circadian clock. Specifically, we will focus on the study of the thermal kinetics 
of LKP2 protein of Arabidopsis thaliana. We also have extended our research to examine the 
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SYNTHESIS OF CRYPTOCHROME MODULATOR 
 
2.1 Introduction 
Cryptochrome (CRY) is an integral part of the mammalian clock system participating in 
the autoregulatory core transcription-translation feedback loop1-3. Recent studies have shown that 
CRY regulates the gluconeogenesis process and hence maintains glucose homeostasis4-6. 
Cryptochrome is a circadian protein that is expressed rhythmically for its function. The 
anticipation was to synthesize a synthetic ligand which stabilizes CRY and prevents it from 
degradation and thereby modulates gluconeogenesis. Modulation of gluconeogenesis will help a 
diabetic patient with a sudden spike in the blood glucose level overnight.  
Recently, a cell-based study showed a carbazole scaffold (KL001) was able to stabilize 
CRY proteins resulting in period lengthening effects. KL001’s action in stabilizing CRY suggested 
potential therapeutic effect towards diabetes and other metabolic diseases7 . Notably, the carbazole 
moiety was found to be essential for that period-changing activity, as it was reported that replacing 
it with a phenyl indole or a non-planar moiety resulted in complete loss
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of activity. Furthermore, its crystal structure indicated that KL001 is bound to the FAD binding 
pocket in the precise location of the isoalloxazine ring, supporting the requirement of a planar 
heterocycle at the core of CRY stabilizing drugs. Despite the fact that carbazole can mimic the 
isoalloxazine ring of the FAD, it lacks critical H-bonding elements that can facilitate efficient 
recognition and binding that could explain the loss of rhythm at higher KL001 concentrations8,9. 
Structure-activity relationships revealed the FAD-binding site is enriched with polar 
residues that bind to polar elements within the isoalloxazine ring of FAD. Therefore, we postulated 
that incorporating heteroatoms into the carbazole scaffold could increase the propensity of 
hydrogen bonding and facilitate recognition and binding of a small molecule9,11.  
The primary purpose of this research is to introduce H-bonding characteristics to the 
carbazole scaffold for efficient binding at the FAD-binding pocket7. In this research, to better 
understand the functional differences of carbazole and other scaffolds, we sought to prepare 
analogs varying in the nature of core scaffold and developed the “Zoltowski library.” In this 
process, we have identified a simple two steps reaction that allows robust formation of delta-
carbolines via benzyne synthesis.  
2.2 Structure-activity relationship of KL001 
The crystal structure of CRY with bound KL001 demonstrated that the carbazole ring of 
KL001 buries itself in the inner cleft of the flavin adenine dinucleotide binding pocket in a manner 
similar to the isoalloxazine ring of FAD. Notably, the isoalloxazine of FAD is subdivided into 
three types of rings: xylene, pyrazine and pyrimidine rings. The pyrimidine ring of the FAD 
participates in the critical hydrogen bonding with the polar residues present in the binding pocket. 
A detailed examination of the crystal structure revealed, carbazole only mimics outer xylene and 
central pyrazine moieties of the isoalloxazine ring and not the complete tricyclic system. Most 
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importantly, carbazole lacks the moieties which can mimic the pyrimidine ring that participate in 
critical hydrogen bonding9,11. (Fig 16) 
 
Figure 16: Comparison of KL001 and FAD: (A): KL001 have carbazole as a scaffold (B): Flavin 
adenine dinucleotide (FAD); the isoalloxazine ring of FAD is subdivided into xylene, pyrazine 
and pyrimidine rings (C) Carbazole only mimics xylene and pyrazine rings of the isoalloxazine 
ring and lacks substituents which can participate in hydrogen bonding with the neighboring polar 
residues in the FAD binding pocket.  
Moreover, a careful examination of the flavin binding site shows the presence of polar 
residues like arginine (R 376) aspartic acid (D 405) and asparagine (N 411), which snuggle close 
to the isoalloxazine ring and participate in significant interactions required for efficient binding. 
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Notably, previous studies have shown that point mutations of aspartic acid (D405) and asparagine 
(N411) are capable of abolishing the interactions between KL001 and CRY2 binding pocket7,9,10. 
(Fig 17, PDB: 4mlp).  
 
 
Figure 17: KL001 in a FAD binding pocket:  The FAD binding site are enriched with polar 
residues. Remarkably, a polar residue arginine 376 (R 376) is just in the vicinity of the carbazole 
ring. Besides, another set of polar residues asparagine (N 411) and aspartic acid (D 405) are 
essential for the KL001 binding.  
All these observations inspired us into incorporating either an extra ring or a polar 
substituent to the scaffold. That might better mimic the size of FAD, filling the FAD binding 
pocket and potentially increasing binding efficiency. Furthermore, introducing substituents with 
 
 43 
hydrogen bonding capabilities might increase the binding efficiency through interactions with 
essential polar residues in the binding site. 
2.3 Synthesis of the Zoltowski Library (ZL series) 
Based on insights gained from the structure-activity relationship of KL001, compounds 
ZL001 to ZL005 were synthesized using different scaffolds while keeping the side chain the same 
as KL001. Our overall design principle of the scaffolds was to either attach a polar side chain or 
an extra ring so that the complete isoalloxazine ring can be mimicked.  
We first synthesized KL001 side chain in bulk to both synthesize KL001 in the lab as a 
reference molecule for biological evaluation and for further attachment of the ZL scaffolds. 
2.3.1 Synthesis of KL001 
 
We synthesized KL001 based on the published synthesis.6 The side chain was synthesized 
by mesylating the furfural amine 1 using mesitylene chloride and pyridine, where pyridine acted 
both as solvent and a base. The mesylated product 2 was then N-alkylated with epibromohydrin in 
the presence of sodium hydride to get compound 3. The coupling reaction of the side chain with 
the secondary amine of carbazole in the presence of sodium hydride yielded KL001 4 (yield 60%). 





Scheme 1: Synthesis of KL001 (20%) 
2.4. Design principle for ZL001 
For the first compound in the library, we did not want to change the scaffold drastically, 
but wanted to introduce an H-bonding moiety. To achieve this, we focused on the carboline 
scaffold. Carbolines are the N-heterocyclic compounds found in many biologically active natural 
and synthetic compounds. Most importantly, β-carbolines are widely distributed in nature and have 
shown DNA intercalation properties to inhibit CDK (cyclin-dependent kinase), topoisomerase and 
monoamine oxidase. Moreover, it interacts with 5-hydroxyserotonin receptors12.  
 Essentially, carbolines are pyrido-indoles, and based on the position of nitrogen with 




























Amongst all carbolines, δ-carboline is extremely rare in nature. Interestingly, benzo fused 
δ-Carboline like cryptolepine and quindoline are found to be pharmaceutically active compounds 
and have shown antimalarial, antiplasmodial and antibacterial activity. Cryptolepine is an 
indoloquinoline natural product extracted from the roost of Cryptolepis triangularis used as a 
traditional antimalarial drug in Central and West Africa for ages13-15. 
We envisioned, δ-carboline being similar to carbazoles will bind in a similar fashion to 
KL001, with the introduction of an H-bonding atom due to a nitrogen at the para position. An extra 
nitrogen can potentially increase the scaffold’s propensity to participate in critical hydrogen 
bonding with the polar residues in the vicinity such as arginine (R 376) (fig 18). Furthermore, it 




Figure 18: ZL001 at the binding site: In ZL001, an extra nitrogen present at the para position 
possibly can enhance the binding efficiency of the compound at the flavin binding site. 
Presumably, it can participate in H-bonding interactions with R 376, N 411. (The fig was made 
using PDB = 4MLP of KL001 complexed with CRY, the nitrogen was introduced to promote 
understanding) 
Delta carboline was primarily synthesized following a known synthesis using aniline as a 
starting material. At first, the amino functionality of aniline was protected with pivolyl chloride in 
the presence of triethylamine as a base yielding pivaloyl amino benzene 5. Amidation served two 
purposes, it not only acted as a protecting group but also provided neighboring group assistance 
during borination at the next step. Subsequent metalation of the compound 5 using nBuLi in 
anhydrous THF followed by the treatment with trimethylborate and subsequent hydrolysis 
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afforded the corresponding boronic acid derivative 5. The product 6 was coupled with 3-fluoro-2-
iodobenzene 7 using Suzuki coupling conditions for 48 hours. The coupled product 8 was 
deprotected in 20% of sulfuric acid solution under refluxing conditions to afford the coupled 
product 9. Cyclization of the resulted compound using pyridine-hydrochloride at 215 oC followed 
by the treatment with ammonium hydroxide afforded δ-carboline 10 in moderate yield16,17.  
3-Fluoro-2-iodopyridine used to couple with the compound 6 was also synthesized based 
on a patented synthesis. Iodination of 3-fluoro-2-chloropyridine was achieved using sodium iodide 
in the presence of trimethylsilane under refluxing conditions18. 
 
Scheme 2: Synthesis of Delta-carboline (45%) 
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The above synthesis of delta-carboline involved several steps under stringent conditions 
demanding longer reaction times with a moderate yield requiring purification in each step. Delta 
carbazoles are essential bioactive molecules. So far, the development of an efficient cyclization 
step was the focus of attention, and not much had been done to modify the coupling reaction. 
Consequently, an efficient approach was needed to synthesize δ-carboline efficiently.   
2.4.1 Synthesis of δ-Carbazole using Benzyne Chemistry 
 
We were intrigued to explore the use of aryne chemistry in the preparation of carbazoles 
due to its feasibility in incorporating heterocyclic rings in various natural product syntheses.  Aryne 
chemistry has proved useful and efficient in the synthesis of complex bioactive heterocyclic 
molecules. Most importantly, aryne chemistry provides a strategic advantage in functionalizing an 
aromatic ring system, because of its feasibility to form multiple carbon-carbon or a carbon- 
heteroatom bond in a single step in a regioselective manner19. 
To synthesize delta carboline through aryne chemistry, we did a retrosynthetic analysis and 
found two plausible approaches: the benzyne approach or the pyridyne approach. We possibly can 
synthesize either benzyne or 2,3-pyridyne precursors which could be coupled with halo-substituted 
aminopyridine or phenylamine respectively to yield the desired product.  
 
Figure 19: Retrosynthetic analysis shows two possible ways delta carbazole could be 
synthesized using aryne chemistry 
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2.4.1a. A 2,3-pyridyne approach for delta carboline synthesis 
 
Pyridyne approach was captivating as the precursor can be coupled with the substituted 
phenylamine, giving an opportunity to synthesize a library of substituted delta carboline with just 
one precursor.  
 
Figure 20: 2,3-Pyridyne approach for the synthesis of delta carbolines: (A) pyridyne precursor 
can be coupled with the halo benzyne, the coupled product can be cyclized to yield delta carbolines.  
(B): Regioselectivity of pyridyne precursor at the 2nd position.  
Regrettably, 2,3-pyridynes are highly regioselective; therefore, nucleophilic substitution 
exclusively takes place at the 2nd position. Incidentally, nucleophilic substitution at the 3rd position 
builds up negative charge on the 2nd position that creates repulsion due to the lone pair of electrons 
on nitrogen20,21. Delightfully, the approach gave the alpha carboline precursor instead, which will 





2.4.1b. A benzyne approach for delta carboline synthesis  
 
It occurred to us that the reaction of o-benzyne with 2-amino-3-halo-pyridine derivative 
should give a (2-halo-pyridin-3yl)-phenyl-amine intermediate that upon intramolecular cyclization 
would give δ-carboline directly. Most importantly, substituted δ-carbazole could also be 
synthesized by using same benzyne precursor with substituted pyridines. On the contrary, a 
different substituent benzyne precursor can also be generated.  
 
Figure 21: Benzyne approach: An in-situ generated benzyne will be coupled with the the ortho-
aminopyridine derivation, subsequent cyliczation yield delta carboline 
Similar to pyridynes, benzyne reaction also pose some restrictions due to the 
regioselectivity effect of different substituents present in the benzyne ring system. Incidentally, 
substituents present in the benzyne dictate the fate of the product; for instance, benzyne precursor 
with the electron donating substituent directs nucleophilic substitution regioselectivity at the meta 
position. Whereas, an electron withdrawing substituents facilitate it at the ortho position. On the 
contrary, a methyl substituent would yield a mixture of products. This restricted us to synthesize a 
library of benzyne precursors in the lab20,21. 
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Several methods for generating o-benzyne were explored that would react with an amino-
pyridine derivative to give a coupled product. Many of the benzyne generation procedures required 
harsh conditions, use of strong bases such as butyllithium (nBuLi) or high temperature. 
Kobayashi’s method of benzyne generation is a milder approach known to generate benzyne in-
situ, and remarkably, the method had been used to generate several natural products. Ortho-
trimethylsilylphenyl triflate is a milder approach to generate benzyne which requires a fluoride 
source which acts as a desilylating agent, which subsequently eliminates the bulky triflate group 
leading to the formation of benzyne in-situ. Any simple fluoride source like cesium fluoride, tetra-
n-butylammonium fluoride can be used at room temperature under an argon atmosphere with 
acetonitrile as a solvent22.  
                     
Figure 22: A mild benzyne precursor: o-Trimethylsilylphenyl triflate: A fluoride source can 





The benzyne precursor (o-trimethylsilylphenyl triflate, 13) was synthesized using recently 
reported synthesis without further optimization. The procedure was highly efficient requiring only 
one purification step with approximately 66% of overall yield. 
Phenol was treated with triisopropyl isocyanate in the presence of catalytic amount of 
triethylamine (Et3N) to yield the corresponding carbamate 11. Ortho-metalation of the carbamate 
11 using nBuLi in anhydrous diethyl ether followed by its silylation and acidic work up afforded 
trimethylsilyl compound 12. Silyl triflate (benzyne precursor 13) was then conveniently formed in 
a one pot carbamate cleavage/ triflation of 12. The carbamate cleavage was achieved by heating a 
solution of 12 in anhydrous acetonitrile with 1-8-diazabicyclo [5.4.0] undec-7-ene (DBU) and 
diethyl amine. Thereafter, N-phenyl-bis-(trifluoromethanesulfonimide) (PhNTf2) was used as a 
triflate source. The compound was then purified using flash chromatography23.   
 
 
Scheme 3: Synthesis of benzyne precursor (66%) 
The coupled product 14 was obtained by allowing benzyne precursor to react with a halo 




























Cesium fluoride was used as a fluoride source to abstract the silyl group to generate benzyne in 
situ24. The coupled product obtained was conveniently microwaved for 10 min at 180 oC with a 
palladium catalyst and sodium acetate in N, N-dimethyl acetamide to obtain the δ-carboline 10 in 
approximately 70% yield25.  
 
 
Scheme 4: Synthesis of Delta-Carboline from benzyne precursor (70%) 
The delta-carboline 10 was coupled with the side chain 3 in presence of sodium hydride and DMF 
to achieve ZL001.   
 
 
Scheme 5: Synthesis of ZL001 (57%) 
Motivated with our success with the aryne chemistry, we used pyridyne precursor to 














































was used for the third compound in the library. ZL002 and ZL003 were designed to gauge if 
planarity of a scaffold is required for the efficient binding in the FAD binding pocket.  
2.5 Design Principle of ZL002 and ZL003 
The design principle for the next two compounds involves the use of alpha carboline and 
delta carboline precursors in place of carbazole.  
 
We anticipated that breaking the central pyrrole ring would allow free rotations of the rings that 
could potentially improve binding capacity by enhancing interactions with other residues. 
Furthermore, it would allow us to understand if planarity is one of the criteria essential for the 
activity of small molecules.    
 
2.5.1. Synthesis of ZL002 
 
As mentioned earlier in the chapter, 2,3-pyridynes are highly regioselective, and all the 
nucleophilic reactions are directed towards the 2nd position (ortho-position). By taking advantage 
of this behavior, we synthesized the coupled product and then linked it with the KL001 side chain. 
We later planned to cyclize the coupled product to generate an alpha carboline, which could 
potentially be used as another scaffold for the library. Regretfully, all our efforts to cyclize the 
















Just like benzyne precursor, a mild pyridyne precursor was synthesized based on the 
published synthesis with minor modifications.  
 
 
Scheme 6: Synthesis of ZL002 (25%) 
The pyridyne precursor 17 was synthesized by silylating the 2-hydroxy pyridine using 
lithium diisopropyl amide as a base to yield silylated derivative 16. The compound 16 was then 
treated with triflic anhydride in the presence of 2,4-lutidine in DCM to achieve pyridyne precursor 
1726. Pyridyne was then generated in situ using cesium fluoride as a fluoride source in anhydrous 
acetonitrile, and then allowed to react with aniline to yield the coupled product 18, which was then 
attached with the side chain to achieve ZL002 19. 
 
2.5.2. Synthesis of ZL003 
 
  For the synthesis of the third compound in the library we used delta carboline precursor as 






























halogen in the binding site. We expected the chloro group might help in facilitating binding by van 
der waals interactions in the flavin binding pocket.  
 The benzyne precursor 13 was coupled with 2-chloro-3-amino pyridine in presence of 
cesium fluoride. Side chain 3 was attached to the coupled product 14 by generating a nitrogen 
anion in presence of sodium hydride, then reaction undergoes ring opening step when heated with 
side chain 3 at 50 oC. 
 
Scheme 7: Synthesis of ZL003 (25%) 
So far, subtle changes were made in the carbazole ring system for the synthesis of a novel 
KL001 analog. It intrigued us to observe the effect if the carbazole is replaced by another known 
tricyclic ring system. Particularly, if the tricyclic system could mimic the structure of natural 
endogenous metabolite which are known to work in the circadian fashion. The design principle of 
the fourth compound in the library relies on using a scaffold similar in the structure of the 
neurotransmitters like serotonin and melatonin. Pinoline is tetrahydro-β-carboline as a scaffold 
and is structurally similar to both serotonin and melatonin and is a natural biological metabolite of 
melatonin. Thus, if it demonstrated physiological effects on circadian period, it could be an 































Figure 23: Natural Metabolite: Structural similarity of pinoline with the natural metabolites, 
serotonin and melatonin  
2.6 Design Principle of ZL004 
 
 
The design principle for ZL004 involved substitution of carbazole with pinoline, which is 
a natural metabolite. Pinoline is tetrahydro-β-carboline and is suggested to be produced in the 
pineal gland during the production of melatonin and is believed to follow the circadian rhythm27-
30. Hence, the anticipation was the scaffold would potentially assist in maintaining the circadian 
rhythm. Besides this, we anticipated that the methoxy group present in the structure could 
potentially participate in much stronger hydrogen bonding with the polar residues in the vicinity. 






capability of the molecule. Pinoline was synthesized by the cyclization of 5-methoxy tryptamine 
by reported synthesis30,31. 
 
 
Figure 24: Structure-activity of ZL004. Pinoline as a scaffold will place two substituents with 
the capability of participating in hydrogen bonding interactions on both sides of the tricyclic ring 
system. The methoxy group, presumably fill the portion of the pyrimidine ring of the isoalloxazine 
ring system. While on the other side, the hydrogen of secondary nitrogen can participate in critical 
interactions with the neighboring residues.The figure was generated using PDB = 4MLP for 






Scheme 8: Synthesis of ZL004 (55%) 
5-Methoxy tryptamine was heated with paraformaldehyde in 10:1 mixture of acetic acid 
and methanol to get pinoline 21. The primary amine of the pinoline was then selectively protected 
with Boc anhydride in THF, the protected scaffold 22 was attached to the side chain 3 of KL001 
using sodium hydride in DMF. The Boc-protected amine 23 was then deprotected using 














































2.7 Design Principle of ZL005 
 
For the fifth compound in the library, benz-quinoxaline derivative was chosen for 
substituting carbazole. The quinoxaline derivative was anticipated to mimic the FAD efficiently 
than carbazole in KL001. We envisioned, presence of one extra ring could potentially enhance pi-
pi stacking and non-covalent interactions between the quinoxaline rings with histidine H 373 
present in the vicinity. Additionally, it can participate in salt bridge formation with asp (D 405) 
and arginine (R 376). Furthermore, just like isoalloxazine ring system, quinoxaline has a pyrazine 

















Figure 25: Structure-acitivity of ZL005: Benzquinoxaline will physically add one more ring in 
the tricyclic ring system, which might potentially eliminate the requirement of having a 
susbstituent in a tricyclic ring system.  
The scaffold was conveniently prepared by the condensation reaction of isatin and o-
phenylenediamine. A solution of isatin and ortho-phenylenediamine in acetic acid was 
microwaved for 10 min at 150 oC to get the desired compound 25 32-33. The scaffold such obtained 






Scheme 9: Synthesis of ZL005 
2.8 Materials and methods 
All the reactions were performed in dried glassware under an argon atmosphere. All 
reagents were purchased from Sigma Aldrich (St. Louis, MO), Fisher scientific (Waltham, MA), 
Alfa Aesar (Ward Hill, MA), Chem Impex (Wood Dale, IL) and used as it was received. The 
deuterated solvents (CDCl3, DMSO-d6) were purchased from Cambridge Isotope Laboratories 
(Cambridge, MA). 1H-NMR and 13C NMR spectra were recorded using 500 MHz Jeol 
multinuclear NMR spectrometer in the department of chemistry at Southern Methodist University. 
All chemical shifts are reported in the standard notation of parts per million using the peak of 
residual proton signals of the deuterated solvent as an internal reference. The coupling constant 
units are in Hertz (Hz) splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet; 
t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; dt, doublet of triplets. Microwave 
reactions were carried out in CEM DiscoverTM. Column chromatography was carried out on 
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N-(Furan-2-ylmethyl)-methane sulfonamide (2) 
Furfuryl amine (20 g, 20.5 mmol, 1 eq.) was dissolved in 150 mL of pyridine under an 
argon atmosphere at room temperature. The reaction mixture was cooled to 0 oC before 
methanesulfonyl chloride (24 mL, 30.8 mmol, 1.5 eq.) was introduced dropwise. The reaction was 
then allowed to stir at the room temperature overnight. The reaction mixture was quenched with 
water, the aqueous layer was extracted with DCM thrice. The combined organic layer was washed 
successively with 5% hydrochloric acid followed by water, brine, dried over sodium sulfate, 
concentrated under vacuum to yield dark brown liquid (32 g, 99%). The compound was confirmed 
by 1H-NMR and used for the next step without further purification. 1H NMR (500 MHz, CDCl3) 
δ7.31 (s, 1H), δ6.32 (d, J =1.75 Hz, 1H), δ5.03 (br, 1H), δ 4.31(d, J = 5.7 Hz, 2H), δ2.82 (s, 3H). 
         
                                                                     3 
N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (3) 
N-(Furan-2-ylmethyl)-methane sulfonamide (20 g, 114 mmol, 1 eq.) was dissolved in N, 
N- formamide (150 mL) at the room temperature under an argon atmosphere. The reaction mixture 
was cooled down to 0 oC -5 oC followed by addition of sodium hydride (60% dispersion in mineral 
oil, 6.80 g, 171 mmol, 1.5 eq.) in portions over the period of 15 min, while it was still stirring over 
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an ice bath. The reaction mixture was allowed to warm up to the room temperature for 30 - 45 min. 
It was again cooled down to 0 oC - 5 oC and added epibromohydrin (12 mL, 171 mmol, 1 eq.) 
dropwise. The reaction flask was then equipped with condenser and the reaction was heated at 50 
oC overnight under an argon atmosphere. The reaction was quenched by adding water and 
extracted with ethyl acetate thrice. Combined organic layer was washed with brine, dried over 
sodium sulfate. Concentration under vacuum afforded 45 g (quant.) brown liquid.  
 
                 4 
N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)-methanesulfonamide 
KL001: (4) 
The carbazole (20 g, 86 mmol, 1 eq.) was dissolved in anhydrous 150 mL of N, N-
dimethylformamide under an argon atmosphere at the room temperature. The reaction mixture was 
further cooled down to 0 oC -5oC for 15 min. To the cooled reaction mixture, added sodium hydride 
(60% dispersion in mineral oil, 5.80 g, 129 mmol, 1.5 eq.) over the period of 15 min. After 
complete addition, the reaction mixture was allowed to stir at room temperature for 30min before 
cooling it down again to 0 -5 oC N-(furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane 
sulfonamide dropwise was then introduced dropwise while the reaction mixture was stirring over 
an ice bath. After complete addition, the reaction flask was equipped with a condenser and heated 
at 50 oC overnight under argon atmosphere. The work up was done by quenching the reaction with 









water followed by the brine solution, dried over sodium sulfate and concentrated under vacuum. 
The crude obtained was then purified by flash chromatography and sticky solid was obtained. The 
sticky solid was crystalized by dissolving in dichloromethane and then adding n-hexane drop wise 
till white crystalline solid settled down in the round bottom flask. The solid was then filtered, 
washed with hexane and dried under vacuum. 7.0 gm of white solid obtained was confirmed by 
1H and 13C-NMR. 1H-NMR (DMSO-d6) δ 8.11 (d, J =7.45 Hz, 1H) δ 7.52 (d, J =8.6 Hz, 3H), δ 
7.43 (t, J = 1.15 Hz, 2H) δ 7.19 (t, J = 8 Hz, 2H) δ 6.28 (t, J = 1.7, 1 H) δ 5.38 (1 H, br, OH, s) δ 
4.48 (m, 2H) δ 4.43 (m, 1H), δ 4.19 (m, 1H) δ 4.10 (s, br., 1H) δ 3.35 (m, 1H) δ 3.20 (m, 1H) δ 
2.88 (s, 3H); 13C NMR (DMSO-d6, 500 MHz) δ 150, 143.75, 140.97, 126.12, 122.65, 120.6, 119.2, 
110.5, 110.0, 68.5, 60.4, 47.4, 45.0, 39.9, 38.2. 
 
                5 
N-phenylpivalamide (5) 
The aniline (5 g, 53.7 mmol, 1eq.) was dissolved in 50 mL dichloromethane at the room 
temperature under an argon atmosphere. The reaction mixture was then cooled down to 0 oC-5 oC 
for 10 min. To the cooled reaction mixture added triethylamine (30 mL, 215 mmol, 4 eq.) followed 
by the addition of pivaloyl chloride (9.9 mL, 805 mmol, 15 eq.) drop wise. The reaction was then 
continued to stir at 0 oC-5 oC for 15-20 min, then allowed to stir at the room temperature overnight. 
The workup was done by concentrating the reaction mixture under vacuum followed by addition 
of 200ml of water. The aqueous layer was then extracted with dichloromethane thrice. The 





of sodium bicarbonate and the brine solution. It was then concentrated under vacuum to yield 
reddish brown solid which was purified by the flash chromatography to get 9.1 g of white solid. 
1H NMR (CDCl3, 500 MHz) δ 7.52 (d, J = 7.4 Hz, 2H) δ 7.30 (t, J = 2.3 Hz, 2H) δ 7.2 (t, J = 1.15 
Hz, 1H) δ 1.31 (s, 9H). 
 
             6 
2-(pivaloylamino)-benzeneboronic acid (6)  
N-phenylpivalamide (5 g, 25 mmol, 1 eq.) was dissolved in 50 mL of anhydrous THF under 
an argon atmosphere at the room temperature. The reaction mixture was then allowed to stir over 
an ice bath followed by dropwise addition of butyl lithium (15 mL, 75 mmol, 3 eq.). After complete 
addition, the reaction mixture was allowed to warm up to the room temperature gradually. The 
reaction mixture was continued to stir at room temperature for 5 hours. After 5 hours, 
trimethylborate was introduced to the reaction mixture drop wise at 0 - 5 oC. After complete 
addition, the reaction mixture was continued to stir at 10 oC for 2 hours. The reaction mixture was 
then quenched by adding 5% hydrochloric acid till its pH became acidic. The aqueous layer was 
then extracted with dichloromethane thrice. The combined organic layer was then washed with 
water, dried over sodium sulfate and concentrated under vacuum. The coffee brown fluffy solid 
obtained was dissolved into the minimum quantity of acetone followed by the addition of water 
dropwise which had crystallized the white solid. The solid such obtained was washed with water 








500 MHz) δ 11.14 (s, br, OH), δ 7.67 (d, J = 8.25, 1 H) δ 7.57 (d, J = 7.45, 2 H) δ 7.20 (t, J = 6.9 
Ar H). 
Alternative synthesis of borate derivative using 2-Bromo-benzylpivaloyl amide (97 mmol) 
was dissolved in 250 mL of anhydrous tetrahydrofuran under argon atmosphere. n-butyl lithium 
(234 mmol) was added drop wise after cooling reaction mixture to -65 to -70 oC (temperature was 
maintained using acetone dry ice mixture). Reaction was continued to stir at -65 to -70 oC for 1 
hour. After 1-hour, triisopropyl borate (250 mmol) was introduced to the reaction mixture drop 
wise over the period of 30 minutes, while it was still stirring at -65 to -70 oC. The reaction mixture 
was then continued to stir at -70 oC for 4 hours. After 4 hours reaction was quenched by adding 
hexane and allowed to warm up to 0-5 oC. Continued stirring for 2 hours lead to generation of 
solid. The solid such obtained was filtered and washed with saturated solution of ammonium 
chloride. The aqueous layer was then extracted with DCM. Combined organic layer was dried over 
sodium sulfate and concentrated. The coffee brown fluffy sold obtained was dissolved in a 
minimum volume of acetone followed by water, which crystallized the white solid. The solid such 
obtained was washed filtered and washed with water. 4 gm. of pure white solid was obtained, 
verified by 1H NMR. 1H NMR (DMSO-d6 500 MHz) δ 11.14 (s, br, OH), δ 7.67 (d, J = 8.25 Hz, 
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2-Iodo-3-fluoropyridine (7) 
3-Fluoro-pyridine (5 g, 38.01 mmol, 1 eq.) was dissolved in 75 mL of 1, 4-dioxane at the 
room temperature under an argon atmosphere. To the solution added chlorotrimethylsilane (9.5 
mL 76.0 mmol, 2 eq.) followed by the addition of sodium iodide (27.5 gm, 190 mmol, 5 eq.). After 
addition, the reaction mixture was allowed to reflux at 80 oC overnight under an argon atmosphere. 
The work up was done by quenching the reaction mixture with water and extracting the aqueous 
layer with ethyl acetate. The combined organic layer was washed with water followed by the brine 
solution, dried over sodium sulfate and concentrated under vacuum. From this approximately 7 
gm of crude compound was obtained. Confirmed by 1H NMR. It was used for further reaction 
without any further purification. 1HNMR (CDCl3, 500 MHz) δ (ppm) δ 8.21 (m, 1H) δ 7.30 (m, 
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2’-Fluoro[1,1’-biphenyl]-2-pivaloylamine (8)  
2-(pivaloylamino-benzeneboronic acid (0.442 g, 20 mmol, 1 eq.) was added to the mixture 
of 2 M potassium carbonate and ethanol at the room temperature. To this mixture 2-Iodo-3-
fluoropyridine (0.445 g, 20 mmol, 1 eq.) dissolved in deoxygenated toluene was introduced. The 
resulting mixture was allowed to stir at room temperature under argon atmosphere for about 1 
hour. Tetrakis-triphenyl phosphorus palladium (0.07 g, 30 mmol, 1.5 eq.) was added to the reaction 
mixture after one hour of stirring at room temperature. The reaction mixture was then allowed to 
reflux at 100 oC for 48 hours. The work up was done by filtering out the solid formed in the reaction 
mixture and drying the organic layer over sodium sulfate followed by concentrating down the 
organic layer under vacuum. The crude such obtained was then purified by flash chromatography 
and then was characterized by 1H NMR. 1H NMR (CDCl3, 500 MHz) δ (ppm) δ 8.44 (dd, J = 16 
Hz, J = 9.2 Hz, 2 H) δ 7.66 (m, 1 H) δ 7.58 (m,1 H) δ 7.41 (t, J = 6.85 Hz, 1H) δ 7.33 (m 1 H) δ 














2’-Fluoro[1,1’-biphenyl]-2-pivaloylamine was refluxed (100 oC) with 20% sulfuric acid 
overnight or until the reaction goes to completion. Adding 2 N sodium hydroxide till the pH 
became basic quenched the reaction. The aqueous layer was then extracted with dichloromethane. 
The combined organic layer was washed with the brine solution, dried over sodium sulfate, 
concentrated under the vacuum. The compound was used for the next step without any further 
purification. 1H NMR (CDCl3, 500 MHz) δ (ppm) δ 8.44 (m, 2 H), δ 7.48 (m, 2 H), δ 7.22 (m, 
3H), δ 6.8 (m, 2H).  
 
             10 
Delta-Carboline (10)  
2’-Fluoro[1,1’-biphenyl]-2-amine (1.5 g, 79.6 mmol, 1 eq.) and pyridinium hydrochloride 
(74 g, 640 mmol, 8 eq.) was refluxed at 210-215 oC for 20-30 minutes. The hot reaction mixture 
was then poured in ice cold ammonia solution and stirred vigorously. The aqueous layer was then 









concentrated under vacuum. The crude such obtained was purified with flash chromatography. 160 
mg of pure compound was obtained, which was further characterized by 1H NMR. MP = 210 oC – 
216 oC. 1H NMR (500 MHz, DMSO-d6) δ 11.39 (s, 1H, NH), δ 8.4 (dd, 1H, J = 1.15 Hz, J = 3.45 
Hz, Py-H), δ 8.16 (d, 1H, J = 7.45 Hz, Py-H), δ 7.8 (dd, 1H, J = 1.15 Hz, J = 6.85 Hz, Py-H), δ 
7.53 (d, 1H, J = 8.6 Hz, Ar-H), δ 7.45 (td, 1H), δ 7.35 (dd, 1H J = 4.6 Hz, J = 4.5 Hz, Ar-H), δ 
7.21 (t, 1H, J = 7.5, Ar-H). 
 
     15 
N-(furan-2-ylmethyl)-N-(2-hydroxy-3-(5H-pyrido[3,2-b]-indol-5-yl)-propyl)-methane 
sulfonamide: (ZL001) (15) 
 
δ-Carbazole (0.160 g, 0.95 mmol, 1 eq.) was dissolved in anhydrous 150 mL of N, N-
dimethylformamide under argon atmosphere at room temperature. The reaction mixture was 
further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added sodium hydride 
(60% dispersion in mineral oil, 1.4 mmol, 1.5 eq.) in batches. After addition reaction mixture was 
allowed to stir at room temperature for 30 min before cooling it down again to 0 - 5 oC. N-(Furan-
2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.219 g, 0.95 mmol, 1 eq.) was then 
introduced to the reaction mixture drop wise while it was stirring over an ice bath. After complete 
addition, the reaction flask was equipped with a condenser and heated at 50 oC overnight under an 










with ethyl acetate. The combined organic layer was washed with water and the brine solution, 
dried over sodium sulfate and concentrated under vacuum. The crude such obtained was 
crystallized by dissolving it in dichloromethane and ethyl acetate mixture and then by adding 
hexane drop wise. White solid such obtained was filtered and further purified by flash 
chromatography. 60 mg (57%) of the pure compound was obtained which was verified by the 1H 
and 13C-NMR. 1H NMR (DMSO-d6, 500 MHz) δ (ppm) δ 8.42 (s, 1H) δ 8.16 (s, 1H) δ 7.85 (s, 
1H) δ 7.46 (m, 4H) δ 7.24 (s, 1H) δ 6.91 (s, 1H) δ 5.72 (s, br, OH) δ 5.31 (s, 1H) δ 4.67 (d, J = 
15.5 Hz, 1H) δ 4.52 (d, J = 15.5 Hz, 1H) δ 4.3 (m 1H) δ 4.2 (m 1H) δ 4.1 (s, br,1H) δ 2.9 (s, 3H). 
13C NMR (DMSO-d6, 500 MHz) δ (ppm) 141.64, 128.35, 127.36, 120.00, 117.39, 110.62, 68.19, 
40.36, 40.20, 40.03.  
 
       11 
Isopropyl-carbamic acid phenyl ester (11) 
Isopropyl isocyanate (2.5 mL ,39.8 mmol, 1.5 eq.) was slowly added to the mixture of 
phenol (4.8 g, 26 mmol, 1 eq.) and triethylamine (1.4 mL, 5.3 mmol, 0.2 eq.) in dichloromethane 
at the room temperature under an argon atmosphere. After stirring at room temperature for 120 
min, it was concentrated down under vacuum. The compound was isolated as white powder, it was 
then analyzed by 1H NMR and gas chromatography and used without further purification. 81% 





Ar-CH), δ 7.1 (d, J = 7.45 Hz, 2H, Ar-CH), δ 4.84 (s, 1H, N-H), δ 3.91-3.88 (m, 1H, CH), δ 1.19 
(d, J = 6.3 Hz, 6H, CH3). 
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Isopropyl-carbamic acid-2-trimethylsilanyl-phenyl ester (Silyl Carbamate) (12) 
A solution of Isopropyl-carbamic acid phenyl ester (2.0 g, 11.2 mmol, 1 eq.) in diethyl 
ether (25 mL) was charged with TMEDA (1.8 mL, 12.2 mmol, 1.1 eq.) and TBSOTf (2.8 mL, 12.2 
mmol, 1.1 eq.) at 0 oC under argon atmosphere. It was gradually allowed to warm up to 25 oC and 
remaining TMEDA (3.35 mL, 22 mmol, 2 eq.) was added. nBuLi (2.5 M, 11.2 mmol, 2 eq.) was 
slowly introduced to the reaction mixture at -78oC over the period of 45 min. The reaction was 
continued to stir at -78 oC for 60 min. After that, trimethylsilyl chloride (5.0 mL, 39 mmol, 3.5 
eq.) was added over the period of 35 min and the reaction was continued to stir at -78 oC for 90 
min. The reaction mixture was quenched by a saturated solution of sodium bisulfate (200 mL), and 
the reaction was gradually allowed to warm up to room temperature. Work up was done by 
separating the organic layer; the organic layer was further washed with sodium bisulfate solution, 
dried over sodium sulfate and concentrated under vacuum. The white solid such obtained was 
analyzed using 1H NMR and used without purification. Yield: 77%. 1H NMR (500 MHz, CDCl3) 
δ 7.4 (d, J = 6.3 Hz, 1H, Ar-CH), δ 7.3 (m, 1H, Ar-CH), δ 7.16 (t, J = 7.4 Hz, 1H, Ar-CH), δ 7.1 
(t, J = 7.4 Hz, 1H, Ar-CH), δ 4.8 (s, 1H, NH), δ 3.9 (m, 1H, CH), δ 1.2 (d, J = 5.7 Hz, 6H, CH3), 







         13 
Trimethylsilyl-2-phenyltriflate (Benzyne Precursor) (13) 
1, 8-Diazabicyclo-[5.4.0]-undec-7-ene (DBU) (3.80 mL, 26 mmol, 1.5 eq.) and 
diethylamine (2.15 mL, 20 mmol, 1.2 eq.) was slowly introduced to the solution of silyl carbamate 
(4.38 g, 17 mmol, 1 eq.) in acetonitrile (30 mL) at room temperature under an argon atmosphere. 
The mixture was then heated at 40 oC for 45 min. It was then cooled down to room temperature; a 
solution of PhNTf2 (9.3 g, 26 mmol, 1.5 eq.) in acetonitrile (25 mL) was slowly introduced drop 
wise over the period of 15 min. The resulting mixture was continued to stir at the room temperature 
under argon atmosphere for 120 min. The workup was done by washing the organic layer with 
saturated solution of sodium bisulfate and 10% sodium hydroxide solution twice. The organic layer 
was then dried over sodium sulfate, concentrated under vacuum. The resulting crude liquid was 
purified by flash chromatography and verified by 1H NMR. Yield % = 65. 1H NMR (500 MHz, 
CDCl3) δ 7.54 (dd, J =5.6 Hz, 1H, Ar-CH), δ 7.45-7.42 (m, 1H, Ar-CH), δ 7.35-7.32 (m, 2H, Ar-
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 (2-Chloro-pyridin-3-yl)-phenyl-amine (14) 
3-Amino-2-Chloro pyridine (0.86 g, 6.7 mmol, 2 eq.) dissolved in acetonitrile (15 mL) was 
added to oven dried cesium fluoride (1.02 g, 6.7mmol, 2 eq.) under an argon atmosphere at the 
room temperature. Trimethylsilyl-2-phenyltriflate (1.0 g, 3.35 mmol, 1 eq.) dissolved in 
acetonitrile (40 mL) was slowly introduced to the reaction mixture over the period of 8 hours, by 
using a syringe pump. The reaction mixture was continued to stir for next 8 hours after complete 
addition. The reaction was monitored by thin layer (3:7 EtOAC:Hexane) and gas chromatography. 
The reaction was quenched by water; the aqueous layer was then extracted by ethyl acetate thrice. 
The combined organic layer was further washed with water and brine, dried over sodium sulfate, 
concentrated under vacuum. The crude solid such obtained was purified by flash chromatography 
Yield = 41%. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 4.6 Hz, 1H, Py-H), δ 7.5 (d, J = 8 Hz, 
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5H-pyrido [3, 2-b] indole (δ-Carbazole) (10) 
(2-Chloropyridin-3-yl)-phenylamine (0.153 g, 0.75 mmol, 1 eq.) was mixed with sodium 
acetate (0.249 g, 1.83 mmol, 2.5 eq.) and Pd (PPh3)2Cl2 (0.042 g, 0.053 mmol, 8 mol%) in a 10 
mL microwave vial. The vial was then flushed with argon for 5 min. N, N-Dimethyl acetamide (1 
mL) was then added to the mixture, which was flush with argon for another 5 min. The vial was 
then heated to 180 oC in CEM DiscoverTM microwave oven at a power level 100 W for 10 min. 
The reaction mixture was then cooled down to room temperature, diluted with 60 mL of methanol 
and concentrated under vacuum. The crude product was purified by flash chromatography. The 
compound was isolated as a white solid in a 70% yield. MP = 210 oC – 216 oC. 1H NMR (500 
MHz, DMSO-d6) δ 11.39 (s, 1H, NH), δ 8.4 (dd, 1H, J = 1.15 Hz, J = 3.45 Hz, Py-H), δ 8.16 (d, 
1H, J = 7.45 Hz, Py-H), δ 7.8 (dd, 1H, J = 1.15 Hz, J = 6.85 Hz, Py-H), δ 7.53 (d, 1H, J = 8.6 Hz, 
Ar-H), δ 7.45 (td, 1H), δ 7.35 (dd, 1H J = 4.6 Hz, J = 4.5 Hz, Ar-H), δ 7.21 (t, 1H, J = 7.5, Ar-H). 
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3-Trimethylsilanyl-1H-pyridin-2-one (16) 
2-Hydroxypyridine (3.0 g, 31.5 mmol, 1 eq.) was dissolved in diethyl ether (75 mL) under 









ice bath (0 oC to 5 oC) for about 10-15 min. After that, lithium diisopropylamide (2 M, 34.5 mL 
69.3 mmol, 2.2 eq.) was drop-wise introduced to the cooled reaction mixture. After complete 
addition, reaction mixture was continued to stir over an ice bath for 10 min, chlorotrimethylsilane 
(6.2 mL, 72.5 mmol, 2.3 eq.) was slowly added to the reaction mixture while it was still stirring 
over an ice bath (0 oC -5 oC). The reaction mixture was then gradually warmed up to the room 
temperature and continued to stir overnight. Workup was done by filtering out the solid generated 
in the reaction, the filtrate such obtained was concentrated under vacuum. The column 
chromatography of the crude afforded 1.72 g white solid. 1H NMR (500 MHz, CDCl3) δ 7.60 (d, 
J = 4.55Hz, 1H) δ 7.44 (dt J = 2.3 Hz, J = 6.85 Hz, 1H) δ 6.32 (m, 1H) δ 0.27 (s, 9H). 
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Trifluoro-methanesulfonic acid 3-trimethylsilanyl-pyridin-2-yl ester (pyridyne precursor) 
(17) 
3-Trimethylsilanyl-1H-pyridin-2-one (1.72 g, 10.2 mmol, 1 eq.) was dissolved in DCM (10 
mL) under argon atmosphere. 2,6-lutidine (1.4 mL, 12.3 mmol, 1.2 eq.) was then introduced to the 
reaction mixture drop-wise. Furthermore, reaction mixture was allowed to cool down to 0 oC, for 
5 min., triflic anhydride (2 mL, 11.3 mmol, 1.1 eq.) was then gradually introduced to the cooled 
reaction mixture. Reaction mixture was then warmed up to room temperature and continued to stir 
with continuous monitoring by thin layer and gas chromatography. Allowed it to stir overnight at 
room temperature under argon. Reaction mixture was concentrated under vacuum and directly 






(dd J = 4.6 Hz, J = 2.25 Hz, 1H) δ 7.90 (dd, J = 4.9 Hz, J = 7.4 Hz, 1H) δ 7.30(dt, J=5.15Hz, 




Aniline (0.30 g, 3.2 mmol, 1 eq.) dissolved in acetonitrile (10 mL) was added to cesium 
fluoride (1.5 g, 9.6 mmol, 3 eq.) under argon atmosphere at room temperature. The pyridyne 
precursor (1.04 g, 3.5 mmol, 1.1 eq.) dissolved in acetonitrile (10 mL) was slowly introduced to 
the reaction mixture. The reaction was continued to stir for next 8 hours after complete addition. 
The reaction was monitored by thin layer (3:7 EtOAc:Hexane) and gas chromatography. The work 
up was done by quenching the reaction with water; aqueous layer was then extracted by ethyl 
acetate thrice. Combined organic layer was further washed with water and brine, dried over sodium 
sulfate, concentrated under vacuum. The crude was purified by flash chromatography, isolated as 
yellow solid. Yield = 41%. 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 1.15 Hz, 1H), δ 8.42 (d, J 










                  19 
N-(furan-2-ylmethyl)-N-(2-hydroxy-3-(phenyl(pyridin-2yl)-amino)-propyl)-methane 
sulfonamide (19) 
N-phenylpyridin-2-amine (0.160 g, 0.95 mmol, 1 eq.) was dissolved in anhydrous 10 mL 
of N, N-dimethylformamide under an argon atmosphere at the room temperature. The reaction 
mixture was further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added 
sodium hydride (1.4 mmol, 1.5 eq.) in batches over the period of 15 min. After complete addition, 
the reaction mixture was allowed to stir at the room temperature for 30 min before cooling it down 
again to 0 - 5 oC. To the cooled reaction mixture N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-
methane sulfonamide (0.219 g, 0.95 mmol, 1 eq.) dissolved 5 mL of DMF was introduced drop 
wise. After addition, the reaction flask was equipped with a condenser and heated at 50 oC 
overnight under an argon atmosphere. The work up was done by quenching the reaction mixture 
with water and extracting it with ethyl acetate. The combined organic layer was washed with water 
followed by the brine solution, dried over sodium sulfate and concentrated under vacuum. The 
crude such obtained purified by the flash chromatography. 75 mg of pure compound was obtained. 
The compound was characterized by 1H NMR. 1H NMR (500 MHz DMSO-d6) δ 8.07 (d, J = 1.1 
Ar-H), δ 7.40-7.24 (m, 6-Ar-H), δ 7.54 (d, J = 1.2 Ar-H), δ 6.62 (d, J = 1.5 1Ar-H), δ 6.3-6.2 (m, 
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2,3,4,9-Tetrahydro-1H-β-carboline (Pinoline): (21) 
5-methoxytryptamine (2 g, 10.5 mmol, 1 eq.) was dissolved 10:1 mixture of acetic acid (38 
mL) and methanol (3.8 mL) at the room temperature under an argon atmosphere. 
Paraformaldehyde (0.380 g, 12.6 mmol, 1.2 eq.) was then slowly introduced to the reaction mixture 
at room temperature. The solution was then heated at 80 oC for an hour, reaction was continuously 
monitoring by the gas chromatography. The mixture was then basified with ammonium hydroxide 
solution. The aqueous layer was extracted with DCM thrice. The combined organic layer was 
washed with water followed by the brine solution, dried over sodium sulfate and concentrated. 
1.56 g of brown solid obtained which was purified by flash chromatography followed by column 
chromatography. The white solid obtained was verified by the 1H NMR. 1H NMR (500 MHz, 
DMSO- d6) δ 10.3 (s, br,1H) δ 7.11 (d, J = 9.2 Hz, 1H) δ 6.80 (s, 1H) δ 6.59 (dd, J = 2.3 Hz, J = 
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tert-butyl-6-methoxy-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]-indole-2-carboxylate (22) 
Boc anhydride (2.3 g, 7.72 mmol) was dissolved in THF (70 mL) at the room temperature 
under an argon atmosphere. The reaction mixture was then allowed to stir at 0 oC over an ice bath 
for 10 min. 1.56 g of pinoline dissolved in THF (10 mL) was then slowly introduced to the cooled 
reaction mixture dropwise. After that, the reaction was allowed to stir at room temperature 
overnight. The reaction was quenched by a saturated solution of sodium bicarbonate (30 mL). The 
aqueous layer was then extracted with diethyl ether thrice. The combined organic later was washed 
with water followed by the brine solution, dried over sodium sulfate and concentrated. Flash 
chromatography of the crude afforded 0.930 g white solid, which was confirmed by 1H NMR. 1H 
NMR (CDCl3, 500 MHz) δ 7.20 (d, J = 8.6 Hz, 1H) δ 6.92 (s, 1H) δ 6.8 (dd, J = 2.25 Hz, J = 8.55 
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9-[3-(Furan-2-ylmethyl-methanesulfonyl-amino)-2-hydroxy-propyl]-6-methoxy-1,3,4,9-
tetrahydro- β-carboline-2-carboxylic acid tert-butyl ester (23)  
tert-butyl-6-methoxy-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]-indole-2-carboxylate (0.710 g, 
2.34 mmol, 1 eq.) was dissolved in DMF (15 mL) under an argon atmosphere at the room 
temperature. The reaction mixture was further cooled down to 0 oC -5 oC for 15 min. To the cooled 
reaction mixture, added sodium hydride (60% dispersion in mineral oil, 1.08 g, 4.60 mmol, 1.5 
eq.) in batches over the period of 15 min. After complete addition, the reaction mixture was 
allowed to stir at room temperature for 30 min before cooling it down again to 0 oC -5 oC. N-
(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.542 g, 2.34 mmol, 1 eq.) 
dissolved in 10 mL of DMF was introduced into the reaction mixture drop wise while it was stirring 
over an ice bath. After complete addition, reaction mixture stirred at the room temperature 
overnight under an argon atmosphere. Work up was done by quenching the reaction with the 
saturated solution of ammonium chloride and extracting it with ethyl acetate thrice. The combined 
organic layer was washed with water followed by the brine solution. It was then dried over sodium 
sulfate and concentrated under vacuum. The crude obtained was then purified by flash 
chromatography yielding 0.590 gm of sticky white solid. The compound was used for the 
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N-Furan-2-ylmethyl-N-[2-hydroxy-3-(6-methoxy-1,2,3,4-tetrahydro-β-carboline-9-yl)-
propyl]-methane sulfonamide (24) 
9-[3-(Furan-2-ylmethyl-methanesulfonyl-amino)-2-hydroxy-propyl]-6-methoxy-1,3,4,9-
tetrahydro- β-carboline-2-carboxylic acid tert-butyl ester (0.50 g, 0.93 mmol, 1 eq.) was refluxed 
with trifluoroacetic acid (0.722 mL, 9.30 mmol, 10 eq.) in DCM (5.00 mL) for 1 hour. The reaction 
was quenched by water (10.0 mL), basified by solution of 2 M sodium hydroxide. The aqueous 
layer was extracted with DCM thrice. The combined organic layer was washed with water 
followed by brine, dried over sodium sulfate and concentrated. Column chromatography afforded 
0.170 g of the white solid. 1H-NMR (CDCl3, 500 MHz) δ 7.3 (s, 1H) δ 7.14 (d, J = 9.15 Hz, 1H) 
δ 6.92 (d, J= 2.3 Hz, 1H) δ 6.82 (dd, J = 2.85 Hz, J = 9.15 Hz 1H) δ 6.31 (m, 1H) δ 6.17 (d, J = 
2.9, 1H) δ 4.52-4.39 (m, 2H) δ 4.04-3.9 (m, 5H), δ 3.84 (s, 3H) δ 3.29 (q, J = 7.45, 1H) δ 3.22-
3.11 (m, 3H) δ 2.79 (s, 3H). 13C NMR (DMSO-d6, 500 MHz) δ 150.08, 143.87, 111.17, 110.65, 
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6H-indolo[2,3-b]-quinoxaline (25) 
A mixture of isatin (0.6 g, 4.07 mmol, 1 eq.) and ortho-phenylenediamine (0.438 g, 4.07 
mmol, 1 eq.) was dissolved in acetic acid (7 mL) in a microwave tube equipped with a septum. 
The reaction was microwaved at 150 oC at the power level 160 W for 10 min. The reaction mixture 
was neutralized by pouring into an ice-cold saturated solution of sodium bicarbonate (250 mL). 
The aqueous layer was extracted with the ethyl acetate thrice. The combined organic layer was 
then washed with water followed by brine, dried over sodium sulfate and concentrated. The yellow 
color crude such obtained was recrystallized with ethyl acetate. To do so, the solid was dissolved 
in boiling ethyl acetate and stored in refrigerator overnight. The yellow needle solid such obtained 
was analyzed by 1H NMR. 1H-NMR (CDCl3, 500 MHz) δ 8.89 (s, br, NH), δ 8.48 (d, J = 7.45 Hz, 
1H) δ 8.33 (dd, J = 8 Hz, J = 9.15 Hz, 1H) δ 8.11 (dd, J = 6.85 Hz, J = 8 Hz, 1H) δ 7.79 (t, J = 
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N-(3-Benzo[b]carbazol-5-yl-2-hydroxy-propyl)-N-furan-2-ylmethyl-methanesulfonamide 
(26)   
5H-Benzo[b]carbazole (0.360 g, 1.6 mmol, 1.5 eq) was dissolved in anhydrous 10 mL of 
N, N-dimethylformamide under argon atmosphere at room temperature. The reaction mixture was 
further cooled down to 0-5 oC for 15 min. To the cooled reaction mixture, added sodium hydride 
(60% dispersion in mineral oil, 0.080 g, 3.2 mmol, 1.5 eq.) in batches over the period of 10 min. 
Reaction mixture was allowed to stir at room temperature for 1 hour. It was again cooled down to 
0-5 oC and N-(Furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)-methane sulfonamide (0.231 g, 0.95 
mmol, 1 eq.) dissolved in 10 mL DMF was slowly introduced. After complete addition reaction 
mixture was then equipped with condenser and refluxed at 50 oC overnight under argon 
atmosphere. Work up was done by quenching the reaction with water and extracting it with ethyl 
acetate thrice. The Combined organic layer was washed with brine, dried over sodium sulfate and 
concentrated under vacuum. Purification by flash chromatography followed by recrystallization in 
ethyl acetate afforded yellow solid. 1H NMR (CDCl3, 500 MHz) δ 8.44 (d, J = 8 Hz, 1H) δ 8.30 
(dd., J = 8.05 Hz, J = 8.75 Hz, 1H) δ 7.76 (dt, J = 1.15 Hz, 1H) δ 7.68 (q, J = 7.45 Hz, 2H) δ 7.54 
(d, J = 8 Hz, 1H) δ 7.38 (t, J = 6.9 Hz, 1H), δ 7.23 (s, 1H) δ 6.19 (d, J=1.7Hz, 1H) δ 5.13 (s, br., 











(s,1H). 13C NMR (CDCl3, 500 MHz) 149, 146, 144, 142, 140, 138, 131, 129.5, 127.3, 121, 119, 
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INTRODUCTION OF NOVEL SIDE CHAINS 
 
3.1 Introduction 
KL001 is a drug which is known for its period altering effect. Remarkably, KL001 is found 
to lengthen the circadian period of cryptochrome1-3, which regulates gluconeogenesis4. 
Incidentally, the structure-activity relationship of KL001 revealed that the carbazole moiety lacks 
critical hydrogen bonding with the essential polar residues in the binding pocket. After the detailed 
investigation it was found that the side chain of the KL001 can also be modified for the improved 
binding. In the previous chapter, different analogs were synthesized with either a polar moiety in 
the ring system or with an extra ring. In this chapter, however, the focus will be on modifying the 
linker and the side chain of the KL0015. Furthermore, another focus will be on making different 
analogs of KL0442, which recently have shown similar or better activity than KL001.  
 
3.2 Structure-Activity relationship of KL001 side chain 
Crystal structure of the KL001 side chain revealed that the furan ring of the side chain 
embed itself close to the residues enriched with aromatic and polar substituents5. Particularly,
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tryptophan (W 310) and glutamine (Q 307) are oriented very close to the furan ring. Therefore, 
modifying the side chain with the substituents having a propensity to participate in the pi-pi 
interactions or in hydrogen bonding will presumably enhance the binding efficiency of the small 
molecule5.  
 
Figure 26: Structure-activity of the KL001 side chain: The side chain binding site is enriched 
with the aromatic and the polar residues. The furan ring of the KL001, snuggles close to the 
tryptophan (W 310) and polar glutamine (Q 307) residues. 
While our work was ongoing, Lee et al., had designed a compound named KL044 which 
had a different side chain and linker. In KL044, the isopropyl linker of the KL001 was replaced 
by an amide linkage, while 2-cyano-6-chloro amine was used as a side chain. Structure-activity 
relationship of KL044 had revealed, the amide linker participates in critical hydrogen bonding 
interactions with the histidine and serine in the vicinity. While the carbonyl of amide interacts with 
the serine (S 394) (3.06 Å) and amino functionality participates in hydrogen bonding interaction 
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with 2.35 Å away histidine residue (H 357). Furthermore, the disubstituted benzyl group forms pi-
pi interaction with the tryptophan in the vicinity2. 
 
 
Figure 27: Structure-activity relationship of KL044: In KL044 the isopropyl linker is replaced 
by the amide linkage. The amide linkage participates in important interactions with the polar 
residues present in the binding pocket. While carbonyl functionality of the amide linker forms a 
hydrogen bond with the histidine 2.3 Å away, the serine residue forms a critical hydrogen bonding 
with the NH functionality of amide.   
Gaining insights from our detailed outlook on the structure-activity relationship and KL044 
interactions, we diverted our focus on to modify the side chains and the linker in rest of the 
Zoltowski library. To accomplish that, we used several different side chains with the propensity of 
participating in CH-pi interactions and hydrogen bonding. 
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3.4. Design principle of ZL006 
        
For the sixth compound in the library nitrogen and sulfur containing bicyclic ring systems 
were used as a side chain in lieu of methane sulfonamide and furan ring. Additionally, the isopropyl 
linker was replaced by an amide linkage. 
Benzothiazole was strategically chosen as a side chain for the carbazole in ZL006. A 
benzthiazole ring system resembles tryptophan ring, remarkably, two of the tryptophan residues 
are present near the side chain binding site (W 310 and W 417). We envisioned the bicyclic 
structure of the side chain could participate in π stacking interactions with the two-tryptophan 
present, also potentially participate in a stronger hydrogen bond. Most importantly, the 
benzothiazole nucleus itself is known to have antimicrobial, antidiabetic and antiviral and anti-
inflammatory properties6-9. Besides this, the modified amide linker is anticipated to participate in 
hydrogen bonding interactions with the neighboring histidine and serine.   
 In order to synthesize the side chain, 6-benzothiazolamine was treated with 
chloroacetylchloride in the presence of triethylamine in DCM at room temperature to obtain N-
benzothiazolchloroacetamide 27. It was then coupled to the carbazole in presence of sodium 













 Scheme 10: Synthesis of ZL006 (35%) 
3.5 Design Principle of ZL007 
 
 
Imidazo-[2,1-b]-[1,3,4]thiadiazole was used as a side chain for ZL006. Several natural 
products having Imidazo-[2,1-b]-thiadiazole moiety10-12 had have been shown to have biological 
activity29. We anticipated Imidazo-[2,1-b]-[1,3,4]thiadiazole ring would participate in π-π 
interaction with trp-290, on the other hand, the extra benzene ring could snuggle itself deep inside 
the cavity and could potentially participate in π- π stacking with W 310 and W 417. Besides this 


































Scheme 11: Synthesis of ZL007 (15%) 
The side chain was synthesized by the published synthesis with a few modifications12. 2-
Thiazolamine was refluxed with 2-bromoacetophenone in ethanol overnight to obtain 2-
phenylimidazo[2,1-b]-thiazole 28. The cyclized product obtained was then heated with chloro- 
acetyl chloride in 1,4-dioxane to get chloroacetyl derivative of 2-phenylimidazo[2,1-b]-thiazole 


































3.6 Design Principle of ZL008 
 
The design principle of another compound in the library was to keep the side chain similar 
to KL001 while replacing the linker to amide. The idea was to replace the side chain furan ring 
with another heterocyclic five-membered ring system, possibly, with 1,3 azoles. We chose to 
introduce 1,3-thaizole as a new side chain owing to its capability of larger pi delocalization than 
the corresponding oxazole.  
In order to synthesize the side chain, 2-amino-thiazole was treated with chloroacetyl 
chloride in the presence of triethylamine in dichloromethane at room temperature to obtain N-
benzothiazolchloroacetamide 32. It was then coupled with carbazole in the presence of sodium 
hydride in DMF to obtain ZL008 33. 
 






























3.7 Design Principle of ZL009 
 
 
Until now, the compounds synthesized were similar to KL001; modifications were done 
either on the scaffold while keeping the side chain same or vice versa. For the 9th compound, 
however, we had designed a novel compound in the library, by using one of the new scaffolds and 
a side chain. For this compound based on our detailed investigation of structure activity 
relationship, we used 5H-Benzo[b]carbazole 5 as a scaffold and benzo-thiazolchloroacetamide 27 
as a side chain, attached by an amide linker. We anticipate the four-ring system can possibly mimic 
isoalloxazine ring efficiently, unlike carbazole which can only mimic xylene and pyrazine rings of 
the whole isoalloxazine ring system. Furthermore, we chose benzo-thiazole side chain because of 
its structural similarity with the tryptophan ring system present in the vicinity. The compound was 
synthesized by coupling 5H-Benzo[b]carbazole 5 with benzo-thiazolchloroacetamide 27 in the 
presence of sodium hydride and N, N-dimethylacetamide under argon atmosphere.   
 




























3.8 Design Principle of ZL010 
The last compound in the library was synthesized by keeping in mind that there were 
several polar residues present in the side chain binding pocket like glutamine (Q 307). 
Furthermore, as mentioned earlier, KL044 having a benzene ring with substituents facilitated 
binding and showed better activity than KL001. Therefore, we selected tri-methoxy benzene ring 
to make another variant of KL044. 
 
 
The side chain 35 was synthesized by treating 3,4,5-trimethoxyaniline with chloroacetyl 
chloride in the presence of triethylamine as a base in dichloromethane at room temperature. The 
side chain was then linked with carbazole in the presence of sodium hydride in DMF to obtain 
ZL010 36. 
 

































3.9 Materials and methods 
All the reactions were performed in the dried glassware under an argon atmosphere. All 
reagents were purchased from Sigma Aldrich (St. Louis, MO), Fisher scientific (Waltham, MA), 
Alfa Aesar (Ward Hill, MA), Chem Impex (Wood Dale, IL) and used as it was received. The 
deuterated solvents (CDCl3, DMSO-d6) were purchased from Cambridge Isotope Laboratories 
(Cambridge, MA). 1H-NMR and 13C NMR spectra were recorded using 500 MHz Jeol 
multinuclear NMR spectrometer in the Department of Chemistry at Southern Methodist 
University. All chemical shifts are reported in the standard notation of parts per million using the 
peak of residual proton signals of the deuterated solvent as an internal reference. The coupling 
constant units are in Hertz (Hz) splitting patterns are indicated as follows: br., broad; s., singlet; 
d., doublet; t., triplet; q., quartet; m., multiplet; dd., doublet of doublets; dt., doublet of triplets. 
Microwave reactions were carried out in CEM DiscoverTM. Column chromatography was carried 
out on Combi-Flash instrument by using pre-packed silica gel columns 
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N-Benzothiazol-6-yl-2-chloro-acetamide (27)  
6-Aminobenzthiazole (2.70 g, 17.9 mmol, 1 eq.) dissolved in dichloromethane (30.0 mL) 
at the room temperature under an argon atmosphere. Triethylamine (3.00 mL, 21.5 mmol, 1.2 eq.) 
was introduced at room temperature. The reaction mixture was then allowed to stir over an ice bath 
maintained at the temperature of 0 to 5 oC for 15 min. To the cooled reaction mixture, chloroacetyl 







the period of 10 -15 min. After stirring it over an ice bath for 15 min, the reaction mixture was 
allowed to stir at room temperature overnight. The reaction mixture was concentrated, and the 
crude was dissolved in ethyl acetate and water. Aqueous layer was extracted with ethyl acetate 
thrice. The combined organic layer was washed with saturated solution of sodium bicarbonate, 5% 
hydrochloric acid followed by water and brine. It was then dried over sodium sulfate and 
concentrated. Column chromatography of crude solid afforded 2.23 g (55%) of white solid. The 
solid was further recrystallized with acetone. which was confirmed by 1H NMR. 1HNMR (DMSO-
d6) δ 10.58 (s, br., 1H) δ 9.26 (s, 1H) δ 8.49 (d, J = 2.3 Hz, 1H) δ 8.01 (d, J = 12.8 Hz, 1H) δ 7.56 
(dd., J = 8.6 Hz, J = 10.9 Hz, 1H) δ 4.27 (s, 2H).  
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N-Benzothiazol-6-yl-2-carbazol-9-yl-acetamide (28) 
Carbazole (1.00 g, 5.90 mmol, 1 eq.) was dissolved in anhydrous 50 mL of DMF under an 
argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC for 
10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.359 g, 
8.9 mmol) was introduced over the period of 10 min. After complete addition, the reaction mixture 
was continued to stir over an ice bath for 15 min followed by at the room temperature for about 1 








benzothiazol-6-yl-2-chloro-acetamide (1.35 g, 5.90 mmol, 1 eq.) dissolved in 5.00 mL of DMF 
was added to the reaction mixture drop-wise. After that, the reaction flask was equipped with reflux 
condenser and allowed to heat at 50 oC overnight under the argon atmosphere. The workup was 
done by quenching the reaction with water and extracting it with ethyl acetate (3 x 30 mL). The 
combined organic layer was washed with water twice followed by brine and dried over sodium 
sulfate, concentrated under vacuum. The white crude obtained was purified by the flash 
chromatography. The sticky solid such obtained was crystallized by dissolving in dichloromethane 
and then adding n-hexane dropwise till white crystalline solid settled down in the round bottom 
flask. The solid was filtered under the vacuum, dried and confirmed by 1H NMR. 1H-NMR (CDCl3, 
500 MHz) δ 10.77 (s, br., NH) δ 9.23 (s, 1H) δ 8.48 (d, J = 1.75 Hz, 1H) δ 8.14 (d, J = 7.45 Hz, 
3H) δ 8.02 (d, J = 8.6 Hz, 1H) δ 7.58-7.56 (m, 3H) δ 7.41 (t, J = 6.9 Hz, 2H) δ 7.19 (t, J = 8 Hz, 
2H) δ 5.3 (s, 2H). 13C-NMR (500 MHz, DMSO-d6) δ (ppm) 167.12, 155.47, 149.81, 141.28, 
136.98, 134.85, 126.27, 123.64, 122.81, 120.75, 119.62, 119.25, 112.32, 109.88, 40.37.  
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6-Phenyl-imidazo[2,1-b]-thiazole (29) 
The mixture of 2-aminothiazole (1.0 g, 99.7 mmol, 1 eq.) and 2-bromoacetophenone (1.98 
g, 99.7 mmol, 1 eq.) was dissolved in 20 mL ethanol and refluxed overnight. Ethanol was removed 
under vacuum; the crude such obtained was dissolved in water and DCM. The aqueous layer was 
extracted with DCM thrice. The combined organic layer was washed with saturated solution of 






concentrated. The orange colored solid (1.25 g) obtained was taken for next step without further 
purification. 1H-NMR (DMSO-d6, 500 MHz) δ 8.19 (s, 1H) δ 7.90 (d, J = 4.6 Hz, 1H) δ 7.80 (dd, 
J= 1.15 Hz, J = 8.6 Hz, 2H) δ 7.34 (dt, J = 7.45 Hz, J =13.7 Hz, 2H) δ 7.23- 7.21 (m, 2H). 
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2-Chloro-1-(6-Phenyl-imidazo[2,1-b]-thiazol-5yl)-ethanone (30) 
6-Phenyl-imidazo-[2,1-b]-thiazole (1.25 g, 6.25 mmol, 1 eq.) was dissolved in 1,4-dioxane 
in a two necked 50 mL flask, equipped with condenser and an argon balloon. The mixture was 
heated at 70 oC and chloroacetyl chloride (1.5 mL, 18.7 mmol, 3 eq.) was introduced drop-wise. 
After complete addition reaction mixture was continued to stir at 70 oC for 15 min. thereafter, 
refluxed for 3 hours, reaction was monitored through gas chromatography. The reaction mixture 
was cooled down to room temperature and filtered. The residue solid was washed with cold 
ethanol. 0.390 g of pale white solid obtained. 1H-NMR (500 MHz, DMSO-d6) δ 8.48 (d, J = 8.6 
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2-Carbzol-9-yl-(6-phenyl-imidazo[2,1-b]-thiazol-5-yl)-ethanone (31) 
Carbazole (0.210 g, 1.26 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under 
an argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC 
for 10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.075 
g, 1.89 mmol, 1.5 eq.) was introduced over the period of 15 min, and then allowed to stir room 
temperature for 1 hr. After 1 hour of stirring, it was again cooled down to 0 oC -5 oC, and 2-Chloro-
1-(6-Phenyl-imidazo[2,1-b]-thiazol-5yl)-ethanone (0.35 g, 1.26 mmol, 1 eq.) dissolved in 5 mL of 
DMF was added to the reaction mixture drop-wise. After that, the flask was equipped with reflux 
condenser and allowed to heat at 50 oC overnight under argon atmosphere. The reaction was 
quenched with water and extracted with ethyl acetate. The combined organic layer was washed 
with water followed by brine, dried over sodium sulfate and concentrated under vacuum.  The 
flash chromatography purification yielded sticky solid which was crystalized by dissolving in 
dichloromethane and then adding n-hexane drop wise till white crystalline solid settled down in 
the round bottom flask. The solid was filtered, dried and confirmed by 1H-NMR. 1H-NMR (CDCl3, 
500 MHz) δ 7.3 (s, 1H) δ 7.14 (d, J = 9.15Hz, 1H) δ 6.92 (d, J = 2.3 Hz, 1H) δ 6.82 (dd, J = 2.85 
Hz, J = 9.15 Hz 1H) δ 6.31 (m, 1H) δ 6.17 (d, J = 2.9, 1H) δ 4.52-  4.39 (m, 2H) δ 4.04-3.9 (m, 
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2-Chloro-N-(thiazol-2-yl)-acetamide (32) 
2-Aminothiazole (2.00 gm, 19.9 mmol, 1 eq.) was dissolved in dichloromethane (DCM 
30.0 mL) at room temperature under the argon atmosphere. Triethylamine (3.30 ml, 24 mmol, 1.2 
eq.) was then introduced at room temperature. The reaction mixture was then allowed to cool down 
to 0 to 5 oC for 15 min. Chloroacetyl chloride (1.9 ml, 24 mmol, 1.2 eq.) dissolved in 20 mL DCM 
was then dropwise introduced at 0 oC, over the period of 10 min. After stirring it over an ice bath 
for 15 min, the reaction mixture was allowed to stir at room temperature overnight. Concentrating 
it under vacuum afforded crude, which was dissolved in ethyl acetate and water. Aqueous layer 
extracted with ethyl acetate thrice. The combined organic layer was washed with saturated solution 
of sodium bicarbonate, 5% hydrochloric acid followed by water and brine. It was then dried over 
sodium sulfate and concentrated. A column chromatography of crude solid afforded 1.63 g of 
white solid, which was confirmed by 1H NMR. 1H-NMR (500 MHz, CDCl3) δ 7.51 (d, J = 3.45 
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2-(9H-carbazol-9-yl)-N-(thiazol-2-yl)-acetamide (33) 
Carbazole (0.7 g, 4.1 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under the 
argon atmosphere at room temperature. The reaction mixture was cooled down to 0 oC to 5 oC for 
10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.251 g, 
6.3 mmol, 1.5 eq.) was introduced over the period of 10 min, and then allowed to stir room 
temperature for 1 hr. After 1 hour of stirring, it was again cooled down to 0 oC to 5 oC, and 2-
Chloro-N-(thiazol-2-yl)-acetamide (0.740 g, 4.1 mmol, 1 eq.) dissolved in 5 mL of DMF was 
added to the reaction mixture drop-wise. Thereafter, the flask was equipped with reflux condenser 
and allowed to heat at 50 oC overnight under argon atmosphere. Work up was done by quenching 
the reaction with water and extracting it with ethyl acetate. Combined organic layer was washed 
with brine, dried over sodium sulfate and concentrated under vacuum. The crude obtained was 
then purified by flash chromatography and sticky solid was obtained. 1H-NMR (500, MHz, 
DMSO-d6) δ 8.14 (d, J = 7.35 Hz, 2 Ar H), δ 7.54 (d, J =8 Hz, 3ArH), δ 7.48 (d, J = 4.05 Hz, 2 Ar 
H), δ 7.48 (t, J = 8.6, 3 Ar H), δ 7.21-7.18 (m, 3 Ar H), δ 5.3 (s, 2H). 13C-NMR (500 MHz, DMSO-
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N-(benzo[d]thiazol-5-yl)-2-(6H-indolo[2,3-b]-quinoxalin-6-yl)-acetamide (34) 
5a,11a-dihydro-5H-benzo[b]carbazole (0.410 g, 1.87 mmol, 1 eq.) was dissolved in 
anhydrous 15 mL of DMF under the argon atmosphere at room temperature. The reaction mixture 
was cooled down to 0 oC to 5 oC for 10 min. To the cooled reaction mixture, sodium hydride (60% 
dispersion in mineral oil 0.112 g, 2.80 mmol, 1.5 eq.) was introduced over the period of 15min and 
then allowed to stir room temperature for one hr. After 1 hour of stirring, it was again cooled down 
to 0 oC to 5 oC, and N-Benzothiazol-6-yl-2-chloro-acetamide (0.422 g, 1.87 mmol, 1 eq.) dissolved 
in 10 mL of DMF added to the reaction mixture drop-wise. After that, the flask was equipped with 
reflux condenser and allowed to heat at 50 oC overnight under argon atmosphere. Work up was 
done by quenching the reaction with water and extracting it with ethyl acetate. The combined 
organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum. 
The crude obtained was then purified by flash chromatography. The yellow solid such obtained 
was recrystallized with ethyl acetate. 1H-NMR (500 MHz, DMSO-d6) δ 10.81 (s, NH), δ 9.25 (s, 
1 Ar H), δ 8.46 (d, J = 1.7 Hz, 2 Ar H), δ 8.40 (d, J = 7.4 Hz, 1Ar H), δ 8.01 (d, J = 7.4 Hz, 1 Ar 
H), δ 7.77- δ 7.73 (m, 4 Ar H), δ 7.61 (d, J = 8.1 Hz, 1 H), δ 5.43 (s, 2 H). 13C-NMR (400 MHz, 
DMSO-d6) δ (ppm) 166.39, 155.45, 149.78, 145.92, 145.51, 140.26, 139.40, 136.79, 134.78, 
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2-Chloro-N-(3,4,5-trimethoxyphenyl)-acetamide (35) 
3,4,5-Trimethoxyaniline (2.00 gm, 11 mmol) was dissolved in dichloromethane (DCM 
20.0 mL) at the room temperature under argon atmosphere. Triethylamine (1.83 mL, 13 mmol) 
was then introduced at room temperature. The reaction mixture was then allowed to cool down to 
0 to 5 oC for 15 min. Chloroacetyl chloride (1.0 mL, 13 mmol) dissolved in 10 mL DCM was then 
added to the reaction mixture drop-wise at 0 oC, over the period of 10 min. After stirring it over 
ice bath for 15 min, reaction mixture was allowed to stir at room temperature overnight. 
Concentrating it under vacuum afforded crude, which was dissolved in ethyl acetate and water. 
Aqueous layer extracted with ethyl acetate thrice. Combined organic layer was washed with 
saturated solution of sodium bicarbonate, 5% hydrochloric acid followed by water and brine. It 
was then dried over sodium sulfate and concentrated. Flash chromatography of crude solid 
afforded 2.6 g of white solid, which was confirmed by 1H NMR. 1H-NMR (500 MHz, CDCl3) δ 
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2-(9H-carbazol-9-yl)-N-(3,4,5-trimethoxyphenyl)-acetamide (36) 
Carbazole (0.4 g, 2.39 mmol, 1 eq.) was dissolved in anhydrous 10 mL of DMF under 
argon atmosphere at the room temperature. The reaction mixture was cooled down to 0 oC to 5 oC 
for 10 min. To the cooled reaction mixture, sodium hydride (60% dispersion in mineral oil 0.144 
g, 3.59 mmol, 1.5 eq.) was introduced in portions over the period of 10-15 min. Following 
complete addition, the reaction mixture was stirred at room temperature for 1 hour. The reaction 
mixture was cooled down to 0 oC to 5 oC and 2-chloro-1-(6-phenyl-imidazo[2,1-b]-thiazol-5yl)-
ethanone (0.621 g, 2.39 mmol, 1 eq.) dissolved in 5 mL of DMF was introduced dropwise to the 
ice cooled reaction mixture. Thereafter, the flask was equipped with reflux condenser and allowed 
to heat at 50 oC overnight under argon atmosphere. Work up was done by quenching the reaction 
with water and extracting it with ethyl acetate. The combined organic layer was washed with brine, 
dried over sodium sulfate and concentrated under vacuum. The crude obtained was then purified 
by flash chromatography and sticky solid was obtained. The sticky solid was crystalized by 
dissolving in dichloromethane and then adding n-hexane drop wise till white crystalline solid 
settled down in the round bottom flask. The solid obtained was filtered and 1H-NMR (500 MHz, 
DMSO-d6) δ 10.46 (s, NH), δ 8.14 (d, J = 7.5 Hz, 2 ArH), δ 7.54 (d, J = 8 Hz, 2 ArH), δ 7.41 (t, J 
= 1.15 Hz, 2ArH), δ 7.19 (t, J = 1.15 Hz, 2ArH), δ 6.95 (s, 2ArH), δ 5.21 (s, 2ArH), δ 3.67 (s, J = 









135.46, 134.01, 133.97, 126.25, 122.79, 120.73, 119.59, 119.30, 109.85, 109.67, 97.16, 60.71, 
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CELL BASED CIRCADIAN ASSAY 
 
4.1 Introduction 
The design principle of all the compounds in the Zoltowski library relies on the careful 
investigation of the binding pocket of FAD and the structure-activity relationship of the KL001, 
already known for efficient binding and activity. The activity of compounds in the Zoltowski 
library as a cryptochrome modulators is tested by a cell-based luciferase activity using a human 
osteosarcoma U2OS cell lines stably expressing clock reporter Bmal1-dLuc. To our delight, most 
of the compounds of the library showed robust rhythm at all the concentrations tested, and some 
of them delay the rhythm at higher concentrations. This chapter discusses the results obtained from 
the circadian activity assay of the Zoltowski library. Additionally, a comparative study of the 
period shift with that of the KL001is explored.   
4.2 Cell Based Circadian Assay 
For the circadian rhythm assay, it is crucial to select a cell line which shows a robust 
circadian rhythm and can survive longer under confluent conditions, and hence are suitable for 
long-term circadian recordings. Notably, several research groups have used human osteosarcoma 
U2OS cells for the circadian rhythm assay owing to its robust rhythm. Additionally, the rhythmic
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 expression of the clock gene can be monitored noninvasively by using firefly luciferase reporter. 
In most of the cells, the clock genes BmaLI and per2 show robust circadian rhythm. Therefore, for 
our experiments, we used U2OS cells harboring Bmal-dLuc reporter for monitoring circadian 
rhythm following drug administration1,3-5. 
4.2.1: Compounds screening 
 
The protocol of compound screening was adapted from Hirota et al5. The compound 
screening was done in an opaque bottom 96 well plate. After trypsinization, the cells were 
suspended in a batch of culture media and plated 100 µL containing 2000 cells per well. The plate 
was then incubated at 37 oC for 2 days (48 hours) to facilitate the cells to reaching full confluency. 
The cell growth was monitored by plating a clear bottom plate with the same amount of culture 
media in parallel5. 
To measure luminescence, the media was replaced with 100 µl explant media containing 
HEPES buffer to maintain the optimal pH, a B-27 supplement which synchronizes the cellular 
clock and luciferin (1 mM). All the drugs were dissolved in 100% DMSO. The drugs were 
introduced into each well by keeping the DMSO concentration constant. KL001 was used a 
reference drugs, while some of the wells were only supplied with DMSO. The plate was then 
covered with a thin transparent film. The rhythm was then monitored using BioTek cytation 5 plate 
reader. The data was collected for the five consecutive days (120 hours) at the temperature 35 oC, 





4.2.2 Luminescence Analysis   
 
 The luminescence data was analyzed by using R-project computing environment. We used 
the R-code analysis algorithm for curve fitting and data display written by Hirota et al. (2008) 1,5. 
The raw luminescence data were fit using following equation: 
          Luminescence = Baseline + mt + Amplitude (e-kt) cos (2𝜋(𝑡 − 𝑃ℎ𝑎𝑠𝑒)/𝑃𝑒𝑟𝑖𝑜𝑑) 
The output .txt file was used to plot Luminescence vs Concentration graph by using the Origin 
graphing software (Origin Lab 2018). 
In addition to observing the rhythm, period lengths were calculated using another R script 
non-parametric algorithm JTK_Cycle developed by Professor Karl Kornacker (Ohio state 
Univeristy) and Professor John Hogenesch (University of Pennsylvania School of Medicine) 2. The 
output file was then used to plot a bar graph of Period vs. concentration. The period length data 






Figure 28: Schematic representation of the cell-based circadian study: The potency of the 
small compounds to bind with cryptochrome and mimic FAD was tested using BMAL1-dLuc 
reporter. Cryptochrome is a repressor of BMAL1 thereby expression of the BMAL1 can be used 
to monitor the cryptochrome activity. 96 well plate plated with U2OS cells harboring BMAL1-
dluc reporter and the luminescence monitoring was done in the biotek plate reader. The output was 
analyzed by the R computing environment to observe the period altering effects. The curve fitting 
program was used to plot the graph between luminescence vs. time. The JTK cycle was used to 
tabulate the period shift behavior of the compounds. 
4.3 Results and discussions 
The R-computing script was used to analyze the output data obtained from the plate reader. 
The curve-fitting was done using the R-script written by Hirota et al. and the output generated with 
the script was used to plot the graph Luminescence vs. time1. The bar graph period vs. concertation 
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was plotted using the JTK_cycle R-script. Notably, the JTK cycle script was written for the initial 
48 -time points2. Therefore, the bar graph only gives the snapshot of the initial 48 time points while 
the experiment was done for 120 hours with 73 data points.  
4.3.1 Activity of KL001 as a cryptochrome modulator 
 
The activity of KL001 was tested and used as a reference for all small-molecule activity. 
KL001 showed an efficient period-altering ability, consistent with the published reports. At low 
concentrations, the period was delayed by 1.7 hours. However, the rhythms are completely 
abolished at the higher concentrations (8 µM, not shown in the bar graph) indicating that even 
though KL001 even though is a potent drug, it could lead to many other clock-related dysfunctions 
at the higher concentrations. 
 
Figure 29: Activity of KL001: A) KL001 shifts period in the dose-dependent manner, however 
rhythm gets abolished at higher concentration. B) The bar-graph clearly shows a dose-dependent 




4.3.2 Activity of ZL001 as a cryptochrome modulator 
 
While we were still developing the cell lines to analyze the potency of the drugs in altering 
the cellular rhythm, our collaborator Dr. Carrie Partch UC Santa Cruz compared the efficacy of 
ZL001with that of KL001 using live cell luciferase imaging. 
The U2OS cell line expressing luciferase reporter gene administered with the drugs at the 
different concentrations was tested for period altering effects. ZL001 delayed the period at the 
higher concentration without killing the rhythm, at the same time a robust rhythm was observed at 
0.1 µM concentration. The reference drug, KL001 (carbazole-scaffold), however, had abolished 
the rhythm entirely at the higher concentration (24 µM) (blue). The results depicted ZL001 has a 







Figure 30: A comparison of CRY modulators: KL00l (A) and ZL001 (B): X axis: Time (days), 
Y axis: Amplitude of luciferase activity. Both the compounds have shown a period shift. At the 
higher concentration, KL001 abolishes the rhythm while still maintained with ZL001. ZL001 
showed robust rhythm at 0.1 µM (red) concentration (Collaborator: Dr. Carrie Partch UC Santa 
Cruz) 
ZL001 screening was also conducted in our laboratory by the procedure mentioned earlier. 
Our data corroborated the results obtained from the Partch lab. ZL001 was able to maintain the 
rhythm at the lower concentration, while delays the period by 1.7 hours at the higher concentration. 
On the contrary, KL001 is toxic to circadian function at a higher concentration. The result dictates 
that KL001 could potentially have many rhythm related side effects such as sleep deprivation or 
other metabolic diseases, while ZL001 might not as rhythm was maintained at a higher 
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concentration as well. Also, since ZL001 was able to maintain the rhythm at the lower 
concentration, therefore, it could be used to mimic FAD for the biophysical studies.  
 
Figure 31: ZL001 delays rhythm at the higher concentrations: (A) Structure of ZL001 (B) A 
graph of luminescence vs. time shows delayed rhythm at the highest concentration (8 µM, teal) in 
the experimental condition, a slight shift is also seen at 2.7 µM (light brown). (C) A bar graph 
plotted between period vs. concentration shows the period shift from 25.05 (zero drug) to 26.72. 
(D) Comparison of ZL001 with KL001: KL001 shows dose dependent increase in the period shift 
activity, however abolishes the rhythm at the higher concentration, while ZL001 is active at the 





4.3.3 Activity of ZL002 and ZL003 as a cryptochrome modulator 
  
A fascinating result was obtained from the ZL002, and ZL003 compounds; contrary to our 
initial hypothesis, that only planar compounds will be able to mimic FAD and thereby maintain or 
alter the rhythm, both ZL002 and ZL003 altered the period at higher concentrations. Presumably, 
the free rotation of the scaffold might allow it to participate in crucial interactions. The extra 
nitrogen in both compounds might facilitate hydrogen bonding interactions with the polar residues 
in the vicinity. In terms of clock function, ZL002 delayed the rhythm at 0.9 and 2.7 µM 
concentrations by 1.7 hours, while ZL003 demonstrated the same behavior at the higher 
concentration (8 µM). Incidentally, the extra nitrogen along with a chloro group present in the ring 





Figure 32: ZL002 delays rhythm at the higher concentrations: (A) Structure of ZL002 (B) A 
graph of luminescence vs. time clearly shows delayed rhythm at the higher concentrations (0.9 
µM pink and 2.7 µM, brown and) in the experimental condition (C) A bar graph plotted between 
period vs. concentration shows the period shift of 2.7 hours at 0.9 and 2.7 µM. (D) Comparison 
of ZL002 with KL001: KL001 has a better activity at the lower concentration, while ZL002 is 





Figure 33: ZL003 delays rhythm at the higher concentrations: (A) Structure of ZL003 (B) A 
graph of luminescence vs. time clearly shows delayed rhythm at the highest concentration 8 µM 
(teal) in the experimental condition. (C) A bar graph plotted between period vs. concentration 
shows the period shift from 25.05 (zero drug) to 26.72. (D) Comparison of ZL003 with KL001: 







4.3.4 Activity of ZL004 as a cryptochrome modulator 
 
Pinoline was used as a scaffold as it is a natural biological metabolite of melatonin. Thus, 
if it demonstrates physiological effects on the circadian period, it could be an endogenous ligand 
of CRY that modulates activity. Remarkably, Pinoline without any side chain attached had a period 
altering effects at the higher concentration. Notably the period delay of 1.7 hours was seen at 2.7 
and 8 µM concentrations. More importantly, the result indicated that Pinoline is able to bind at the 
flavin binding pocket of the CRY and can potentially be tested for its ability as a natural therapeutic 
agent.  
 
Figure 34: Pinoline, a natural metabolite shows period altering effects: (A) Pinoline showed 
period lengthening effects at higher concentrations, robust rhythm was observed at all the 
concentrations indicating the pinoline binding at the FAD binding site. (B) The period lengthening 
of about 1.7 hours were observed at 2.7 and 8 µM concentrations.  
Intrigued by the results we tested the pinoline scaffold attached with the KL001 like side 
chain. The compound showed robust rhythm at all the concentrations used in the experimental 
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settings. The period lengthening effect of 1.7 hours were observed at 0.9 and 2.7 µM 
concentrations. Particularly, the drug showed robust rhythm indicated by the higher amplitudes in 
the fig 35B implying binding ability of the compound. These latter observations are particularly 
intriguing. The period lengthening effects are consistent with docking to the FAD binding pocket 
to delay CRY degradation, but in contrast to KL001, which suppresses clock function, here we 
observe higher amplitude rhythms consistent with enhanced clock activity. Motivated with our 
initial results, we plan to test the activity of the compound at the higher concentrations.  
 
Figure 35: ZL004 maintains robust rhythm while delays it at the higher concentrations: (A) 
Structure of ZL004 (B) The curve fitting graph depicts robust rhythm was maintained at all the 
concentrations with rhythm delaying affects seen at the higher concentrations.(C)The period 
delaying effect can be clearly visible at 0.9 µM and 8 µM. (D) Comparison between KL001 and 




4.3.5 Activity of ZL005 as a cryptochrome modulator 
 
In ZL005, benz-quinoxaline was used a scaffold with the belief that it will mimic 
isoalloxazine ring efficiently, owing to its four-ring structure. Interestingly, similar to the Pinoline 
scaffold, benz-quinoxaline ring system maintained robust rhythm at all concentrations, with higher 
amplitudes, as shown in fig 36B. More specifically, the compound demonstrated period 
lengthening effects at the higher concentration which clearly indicates binding at the flavin binding 





Figure 36: ZL005 sustained robust rhythm and delayed it consistently at the higher 
concentrations: (A) Structure of ZL005 (B) A curve fitting graph shows robust rhythm which 
gets delayed at the higher concentrations (yellow, teal). (C) A bar graph shows 1.7 hours period 
shift from 0.9 µM to 8 µM concentrations (D) Comparison of ZL005 and KL001: The period 
delaying effect of ZL005 is almost similar to that of KL001 at the 0.9 µM concentration.  
4.3.6 Activity of ZL006 as a cryptochrome modulator 
 
 In the sixth compound the side chain and the linker were modified, while carbazole was 
used a side chain. The result was particularly intriguing, despite ZL006 retaining KL001 like 
carbazole scaffold, ZL006 did not alter the rhythm indicating the compound did not bind the flavin 
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binding pocket. The result indicated that the side chain and the linker also play a critical role in 
the efficient binding of a drug. In future, we plan to test this compound for its activity in the higher 
concentrations to gauge if the concentration plays any role in the binding ability of the compound. 
 
 
Figure 37: ZL006 exhibits robust rhythm with no period alteration affects: (A) Structure of 
ZL006 (B) A graph of luminescence vs. time shows robust rhythm maintained at all the 
concentrations of the drug. (C) A bar graph plotted between period vs. concentration shows no 
period shifts. (D) Comparison of ZL006 with KL001: KL001 has a better activity at the lower 
concentration, while ZL006 has no period altering effects.  
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4.3.7 Activity of ZL007 as a cryptochrome modulator 
 
 For ZL007, the carbazole moiety was retained, however, the side chain and the linker had 
been changed in ZL007. The compound shows no period altering activity, indicating side chain 
might not able be to snuggle close to the tryptophan residues owing to shorter linker used. We 
plan not to use this compound for further studies.  
 
Figure 38: ZL007 shows robust rhythm with no period alteration: (A) Structure of ZL007 (B) 
A graph of luminescence vs. time shows the rhythm maintained at all the concentrations of the 
drug. (C) A bar graph plotted between period vs. concentration shows no period shifts. (D) 
Comparison of ZL007 with KL001: Kl001 has a better activity at the lower concentration, while 
ZL006 has no period altering effects.  
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4.3.8 Activity of ZL008 as a cryptochrome modulator 
 
 In ZL008, an amide linker and a thiazole side chain are used as a side chain while keeping 
the carbazole scaffold similar to KL044 and KL001. The compound lacks any period altering effect 
implying lack of binding at the flavin binding pocket, which is intriguing as carbazole had been 
shown to be essential for the efficient binding in the flavin binding pocket. The result of ZL008 
along with that of ZL006 indicates the side chain of the compound complements the binding ability 
of the carbazole moiety. For instance, in KL044 the electron withdrawing substituents in the side 
chain aromatic ring showed to play an essential role in binding. In future, we plan to use 
substituents in the side chain moiety (indeed, promising results obtained with the tenth compound 





Figure 39: ZL008 has no period altering effects but robust rhythm: (A) Structure of ZL008 
(B) A graph of luminescence vs. time shows rhythm maintained at all the concentrations of the 
drug. (C) A bar graph plotted between period vs. concentration shows no period shifts. (D) 
Comparison of ZL008 with KL001: Kl001 has a better activity at the lower concentration, while 
ZL008 has no period altering effects.  
4.3.9 Activity of ZL009 as a cryptochrome modulator 
 
ZL009 is the novel compound in the library, here the benzquinaxaline ring is coupled with 
the side chain previously used in ZL006. It was intriguing as the compound substantially 
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lengthened the period at the 2.7 µM concentration. Moreover, the result was captivating as the 
rhythm is delayed by 3.3 hours similar to that of KL001. Most importantly, the compound not only 
shifts the circadian period substantially, but also leads to the amplified rhythms (fig 40B), 
particularly, at the 2.7 µM concentration indicating possibly different mode of action.  
 Notably, the four-membered scaffold ring system was selected such that it can overlap or 
mimic the isoalloxazine ring of flavin, while side chain ring system was similar to that of the 
tryptophan present in the side-chain binding pocket. The similar scaffold used in ZL005 (discussed 
above) with the KL001 side chain was also able to delay rhythm by 1.7 hours, on the contrary the 
same side chain used in ZL006 did not alter the rhythm. Further, oscillations were maintained with 
significantly enhanced circadian amplitudes. Such affects are particularly intriguing as decline in 
circadian period have been associated with aging, and age-related physiological impairment. This 
observation enabled us to conclude that possibly, the four-membered scaffold plays a critical role 




Figure 40: ZL009, a novel compound shows both robust rhythm and the period lengthening 
effects: (A) Structure of ZL009. (B) The novel compound maintains robust rhythm at all the 
concentrations, period lengthening observed at 2.7 µM. (C) The bar graph shows a significant 
delay in the period at 2.7 µM concentration. The period delay is about 3.3 hours similar to that of 
KL001 (D) Comparison of ZL009 with KL001: The period lengthening effect at 2.7 µM 






4.3.10 Activity of ZL010 as a cryptochrome modulator 
 
 The tenth compound in the library was synthesized with the insights taken by KL044. The 
structure-activity analysis of KL044 indicated that the substitutes present in the side chain affects 
the binding efficiency of the drug. In ZL010 polar substituents are attached in an aromatic side 
chain with an amide linker and a carbazole scaffold. It was intriguing that the compound 
demonstrates considerable period shifts of 1.7 hours at the higher concentrations but results in 
ablation of circadian amplitude. Mechanistically, these results are consistent with those observed 
for KL001. Combining observations from molecules like KL001, ZL010 (amplitude lowering) and 
ZL009/ZL004 (amplitude enhancing) may facilitate greater understanding of the complexities of 
CRY regulation as it pertains to clock maintenance. The results are captivating, and we plan to use 




Figure 41: ZL010 showed robust rhythm at the lower concentration, while period 
lengthening effects at the higher concentration: (A) Structure of ZL010 (B) A graph of 
luminescence vs. time shows a delayed rhythm at the higher concentrations 2.7 and 8 µM of the 
drug. (C) A bar graph plotted between period vs. concentration shows period shifts by 1.2 hours 
(D) Comparison of ZL010 with KL001: KL001 has a better activity at the lower concentration, 
while ZL010 showed period lengthening effects at the higher concentration.  
4.4 Conclusion 
Although further studies are required, based on our results, we can safely conclude that 
scaffold plays a critical role in the period altering effects. To our delight, the hypothesis of 
introducing polar interactions in the isoalloxazine binding site proved to be essential for the 
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efficient binding. Notably, the introduction of polar moieties in the scaffold was able to maintain 
robust rhythm at the lower concentrations, while some of them like ZL001, ZL004, ZL005 showed 
period altering effects at the higher concentrations. To rationalize the finding, the four-membered 
ring system altered the period similar to that of KL001.  
Furthermore, substituents present in the side chain aromatic ring system facilitate the 
period lengthening effects. For instance, in the Zoltowski library none of the heterocyclic side 
chain used were able to alter the period. However, the trimethoxybenzene side chain delayed the 
rhythm by 2.7 hours. It was intriguing that the tryptophan like side chain used in the ZL006 with 
the KL001-like carbazole scaffold depicted no period altering effects, whereas the same side chain 
in ZL009 with the benz-quinoxaline ring system showed activity similar to that of KL001.  
Even though none of the compounds in the Zoltowski library was able to delay the rhythm 
like KL001, but interestingly none of them had utterly killed the rhythm. Some of the compounds 
in the library can be used for biophysical studies of the signaling mechanism of the cryptochrome.  
With these results in hand, we plan to synthesize different analogs of the four-membered 
ring scaffold with the polar side chain linked with an amide linker. Moreover, the compounds 
which have shown period altering activity, we plan to test their activity at the higher 
concentrations. Additionally, we plan to perform degradation assays to determine the toxicity of 
these drugs.  
4.5 Long-term goals  
 The circadian clock is the prime determinant of all the physiological behavior, given that 
most of the clock related dysfunctions are chronic hence specificity of the drugs is required to 
avoid the potential side effects. The long-term goal of this research is to design the site-specific 
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drugs for the critical circadian proteins and individual interactions. Phenotype-based screening of 
FDA approved chemical library (LOPAC) had led to explore several small molecules having a 
therapeutic effect such as KL0014,8-11. Since the circadian clock is so intricate a target-based drug 
design is needed to avoid fatal side effects. For instance, mammals have two cryptochromes CRY 
1 and CRY2. Since only CRY 2 has been found to be associated with breast cancer,11 therefore, 
site-specific CRY 2 inhibitors could eliminate the off-target effects and thereby the side effects. 
Furthermore, the research can be extended to target individual interactions such as cryptochrome: 
androgen receptors which are associated with prostate cancer. Other significant interactions exsit 
such as CRY:myc, CRY:HIF112.   
In recent years, X-ray crystallography has provided a vast platform for the site-specific 
drug designing. A high-resolution crystal structure of a protein or a protein complex can provide 
better insight into the binding pocket; thereby a site-specific drug can be designed. As we saw 
earlier, KL001 was found to be a potent drug out of several LOPAC screened, but on analyzing 
the crystal structure of CRY2 in complex with KL001 or with FBXL3, they were able to determine 
the mechanistic basis of drug action. Crystal structure revealed the information about the binding 
site which led the same group to synthesize yet another potent drug KL044.  
The long-term goal of our laboratory will be getting the crystal structure of the proteins, 
and individual complexes and from that follow the site-specific drug designing strategy.  
4.6 Materials and methods 
All the cell culture flasks and 96-well plate were ordered from Fischer Scientific. The U2OS cells 
harboring Bmal-dLuc reporter was obtained from ATCC (The American type culture collection). 
All the reagents Dulbecco’s Modified Eagle Media (DMEM) composed of L-glutamine, HEPES, 
sodium bicarbonate. (Gibco 21063029), fetal Bovine Serum (FBS) and antibiotics 
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(penicillin/streptomycin, 100U/ml), luciferin, 2% B27 were ordered from Fischer scientific until 
otherwise reported.  
4.6.1 Cell Culture  
 
 Composition of Medium: (Adapted from Hirota and Kay method). 
A sincere thanks to Samuel G. Weber for the media preparation and cell plating before every 
experiment.  
Culture media: 
DMEM (high glucose, no phenol red) 450 mL 
10% FBS 50 mL 
100unit/ml Penicillin and 100ug/ml 
streptomycin 
5 mL 
1mM Sodium pyruvate 5 mL 
 
Explant media: 
DMEM (high glucose, no phenol red), 
containing 100unit/ml Penicillin and 
100ug/ml streptomycin, HEPES, 1mM 
Sodium pyruvate 
12 mL 
2% B27 2 µL (added just before the experiment) 
Gentamicin 0.1 mg/mL (added just before the experiment) 
Luciferin 1 mM (added just before the experiment) 
 
U2OS cells harboring Bmal-dLuc reporter were maintained in the culture media at 37 oC. 
After trypsinization of the cells, they were seeded in the culture media at the density of 2000 
cells/well in an opaque 96-well plate and incubated at 37 oC for two consecutive days for allowing 
U2OS to reach to the highest confluency. At the same time, a transparent 96-well plate was seeded 
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to monitor the cell growth under the microscope. After two days of incubation, the media was 
replaced by an explant media containing B-27 supplement to reset the clock of the cells. The 
explant media was also supplemented with luciferin.  
4.6.2 Drug Screening 
All the drugs were dissolved in DMSO. The drugs were introduced in each well by keeping 
the DMSO concentration same. KL001 was used as a reference drug, while some of the wells were 
only supplied with DMSO to observe the effect of the neat DMSO. The plate was then covered 
with a thin transparent film. The rhythm was monitored using BioTek Cytation 5 plate reader. The 
data was collected for the five consecutive days (120 hours) at the temperature 35 oC with the 
integration time of 14 seconds and interval time of 1 hour 40 min. The data obtained was used for 
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LOV DOMAIN PROTEIN LKP2 IN A. THALIANA AND B. RAPA 
 
5.1 Introduction 
Plants being sessile have developed robust sensory mechanisms to gauge the surrounding 
environment and adapt to facilitate their growth and development. Out of all environmental cues, 
light is the most important source which plants sense to dictate the developmental process1. Plants 
not only use light for the photosynthetic process but also to regulate several developmental and 
metabolic processes such as photoperiodic flowering, hypocotyl elongation2, stomatal opening3, 
and phototropism4,5, and chloroplast movement6. In order to do so, plants employ several 
photoreceptor proteins which sense broad spectrum of light. The major classes of photoreceptors 
in plants are the blue light photoreceptors, phototropins and cryptochromes, and the red/far-red 
photoreceptors phytochromes7,8. All photoreceptors can sense various wavelength and intensities 




Figure 42: Different photoreceptors in the plant sense light and regulate several physiological 
processes 
All these photoreceptors are well studied at the molecular level for their role in regulating 
plant physiological processes9. Incidentally, in the year 2000 a new kind of the blue light 
photoreceptor family named the ZTL family was identified in Arabidopsis thaliana. The ZTL 
family in A. thaliana includes three members: Zeitlupe (ZTL), flavin binding kelch repeat F-box1 
(FKF1) and LOV kelch protein2 (LKP2)10,11. All these proteins belong to the LOV domain 
superfamily of blue-light photoreceptors. The members of ZTL family were found to work in 
concert to measure the day length and hence to determine the flowering time and to regulate the 
other circadian processes12.To date, the function of ZTL10,15,18 and FKF110,16,17 is well studied in 
A. thaliana. However, not much is known about the function of the third member of the family 
LKP2. This chapter will mainly focus on characterization and understanding the photocycle of 
LKP2 in A. thaliana. In addition, we extend our research to study the important circadian rhythm 
proteins in the Brassicaceae family specifically Brassica rapa, which is an essential agricultural 
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crop that includes turnip, Napa cabbage, Chinese cabbage etc. Since circadian rhythm controls 
several developmental processes, studying crucial circadian protein in important agricultural crop 
can potentially impact the agricultural industry19. 
5.2 LOV Domain 
LOV (Light Oxygen Voltage) domain are blue light photoreceptors, originally discovered 
in the plant phototropins. LOV proteins function as a subset of the Period-Aryl hydrocarbon 
receptor nuclear translocator-Singleminded (PAS) domain superfamily, where LOV domains non-
covalently binds the flavin cofactors (FAD or FMN) as a photo-responsive element10,13,14. The 
PAS fold consists of 5 antiparallel beta strands 2-1-5-4-3 flanked by a series of four a-helices on 
one side of the face termed as “A face”. The A-face acts as the photoreceptor core as it binds with 
the flavin cofactor within a cavity formed by typical a-helices and β-strands arrangement. The B 
face consists of the other side of the beta strands and are typically involved in protein:protein 
interactions in PAS and LOV domain proteins. The primary characteristic of LOV proteins are 
dictated by their flavin chemistry, which plays an important role in determining the activity and 
signal transduction landscape of LOV domain proteins20,21. In Arabidopsis thaliana, LOV domain 
proteins like Zeitlupe (ZTL), flavin binding kelch repeat F-box1 (FKF1) and LOV kelch protein2 
(LKP2) employ small molecule flavin chemistry to measure the day length and hence determine 




Figure 43: Schematic diagram of PAS domain fold: PAS domain is composed of 5 antiparallel  







Figure 44:  Crystal structure of the Zeitlupe exhibiting a typical PAS fold.  
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5.2.1 Flavin chemistry  
 
The photocycle of the LOV domain is chiefly directed by the small molecule cofactor 
flavin adenine dinucleotide (FAD) or flavin mononucleotide (FMN). Flavin chemistry is further 
modulated by the neighboring group interactions or steric constrains in the spatial environment, 
and ultimately the kinetics parameters of the protein21,22. Upon light activation, a covalent adduct 
is formed between the flavin cofactor and a conserved cysteine residue in the LOV core. The 
cysteine residue is present on the Ea region within a conserved GXNCRFLQ motif. With the 
formation of flavin-cysteinyl adduct (C4a) a series of electron and proton transfer reactions occur 
leading to the protonation at the N5 position of the flavin ring. Protonation relays changes in the 
hydrogen bonding network of the protein starting from the flavin binding pocket to the other 
regions of the protein affecting inter-or intra-protein interactions. Upon return to the dark, the 
adduct state undergoes thermal decay back to its ground state that corresponds to dark state with 
lifetimes varying from seconds to days20-24.  
Recently, these variations in the photo-adduct lifetimes was shown to be essential for 
proper function. For instance, ZTL functions at the day-night transition which is supported by its 
relatively short photocycle kinetics with a half-life of 2 hours18. On the other-hand LKP2 has a 
relatively long photo-adduct lifetime with a half-life of approximately six days. Therefore, the 
photo-adduct lifetime may provide some insight in predicting the biological function of the protein.  
5.2.3 LOV photocycle and kinetics 
 
The photo adduct formation reaction can easily be studied in the laboratory setting by 
observing the shift in the UV-vis absorption spectra. Notably, in the dark state the LOV domain 
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protein shows the characteristic absorption spectra of oxidized flavin with peaks at 450nm and 
vibrational bands at 425 nm and 475 nm (Fig. 44C). Upon blue light activation, the isoalloxazine 
ring of flavin forms a covalent linkage with the thiol moiety of a conserved cysteine. Specifically, 
blue light activation promotes oxidized flavin at the dark state into the singlet excited state, that 
undergoes intersystem crossing to form a triplet state. The triplet state, then abstracts an electron 
from the cysteine and generates a radical pair. Subsequent radical recombination leads to the 






Figure 45: Mechanism of the C4a Adduct formation: (A) Upon blue light activation, a 
conserved cysteine residue in GXNCRFLQ motif of LOV domain participates in the C4a adduct 
formation with the isoalloxazine ring of flavin (B), (C) The conversion of light and dark state can 
be monitored by observing the flavin spectra; in the dark state classic flavin peak can be observed 
at 450 nm with the two shoulder peaks at 425 and 475 nm. In light state only one peak is observed 
at 380 nm. (D) Blue light activation excites flavin to the singlet excited state followed by the triplet 
state. Single electron transfer event takes place from the conserved cysteine, which results in the 
formation of a radical pair. The reduced flavin generates upon radical recombination. 
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5.2.4 Factors affecting LOV photocycle 
 
There are several factors which dictate the cofactor flavin chemistry and thereby the LOV 
domain photocycle and the overall structure of the protein. Primarily, there are three factors which 
modulate the flavin photochemistry. First and foremost, is the position of cysteine in the dark state 
protein where two different conformers have been observed that differ according to the proximity 
of the thiol moiety to the C4a position of the isoalloxazine ring. Computational and kinetic studies 
indicate that the light state of the protein is stabilized if the position close to the C4a adduct is 
favored, whereas the conformer favoring the position further away leads to a less-stable adduct.  
Several studies have indicated that introducing residues that sterically bias the cysteine conformer 
to one state or the other can tune adduct state lifetime20,23, 29-31.   
The second factor that controls the C4a adduct stability involves conformational changes 
occurring in the flavin isoalloxazine ring system. C4a adduct formation changes the hybridization 
of the C4a position from the planer sp2 to the tetrahedral sp3 hybridization states, which alters 
steric contacts to the neighboring residues, mostly on the residues below or above the isoalloxazine 
ring system. Thereby, electronic and steric effects of those residues govern the stability of the 
adduct. For instance, Zoltowski et al. showed that the stability of the light state adduct was 
enhanced when isoleucine was introduced at the flavin re-face in a fungal protein Vivid of 
Neurospora crasa.23 
The third crucial factor involves hydrogen bonding and the N5th position of the 
isoalloxazine ring system of flavin. Deprotonation of the N5 proton has been shown to be rate-
limiting in adduct decay. Thus, factors which either stabilize or destabilize the N5 proton directly 
modulate the kinetics of adduct decay. For instance, a conserved glutamine (Q) adopts a position 
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as such that its amino functionality participates in the hydrogen bonding with the O4 of the 
isoalloxazine ring in the dark state. On the contrary, upon blue light illumination; the C4a adduct 
forms which changes the environment at the active site, forces glutamine to flip 180o. The “flipped 
conformation” of the glutamine adopts a conformation such that now its carbonyl functionality 
forms hydrogen bond with the N5th proton, thereby facilitating in proton abstraction.  Later in the 
chapter, we will observe the effect of glutamine flip in the LOV domain photocycle of the LKP2 
protein31,32. 
 
Figure 46: Glutamine Flip: The amino functionality of the glutamine forms a hydrogen bond 
with the O4. Upon blue light activation, the C4a adduct formation leads to the change in the 
hydrogen bonding pattern. As a result, a conserved glutamine flips and orients in such a way that 
the carbonyl functionality of the glutamine forms a hydrogen bonding with the N5H proton.  
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5.3 ZTL Family  
 The Zeitlupe (ZTL) family forms an important subclass of the LOV domain family. They 
are the blue light photoreceptors and play a significant role in both the plant circadian clock and 
in mediating photoperiodic responses. The ZTL family includes three blue light photoreceptor 
proteins: Zeitlupe (ZTL), Flavin bind Kelch repeat 1 (FKF1) and LOV kelch Protein 2 (LKP2). In 
contrast to the other LOV domain proteins, these proteins consist of two unique domains F-box 
and Kelch repeats. Structurally, the F-box domain is flanked by the photo reactive LOV domain 
at the N-terminus and Kelch domains at the C-terminus. The presence of the extra two domains 
provides the ZTL family a unique feature from the other LOV domain proteins; while the LOV 
domain acts as a photo sensory domain and perceives blue light, the other two domains are 
involved in protein degradation and protein-protein interactions. The main function of the F-box 
containing protein is to maintain the pace of the circadian rhythm by regulating the time of day for 
specific ubiquitination of substrate and consequent degradation. In this manner, the ZTL family 





Figure 47: The Schematic representation of domains in ZTL family: ZTL family consists of 
F-box domain flanked by the LOV domain at the N-terminal and six Kelch repeats at the C-
terminal. LOV domain participates in photoactivation, while both F-box and kelch repeats take 
part in ubiquitination process.  
All three members of the ZTL family are known to work in concert to maintain the 
circadian rhythm and photoperiodic flowering. The current model of the ZTL family is as follows: 
During dawn blue light activated LOV domain favors Zeitlupe (ZTL) to form a complex with 
Gigantea (GI), the complex dissociates in dusk and the F-box domain of the ZTL complexes with 
TOC1 (Timing of Cab 1) and PRR5 and to them for proteasomal degradation. FKF1 on the other 
hand, forms a complex with Gigantea and regulates photoperiodic flowering by repressing CDF 
(Cyclin Dof factor)11,18. All these protein target, directly alter gene transcription, thereby 




Figure 48: A schematic representation of circadian and photoperiodic clock in A.thaliana. 
ZTL forms a complex with Gigantia (GI) during the day time, at the same time FKF1 forms a 
complex with GI and degrades Cyclin Dof Factor (CDF), thereby regulate photoperiodic timing. 
At night, ZTL gets dissociated with GI and degrades TOC1 and thereby represses the transcription 
of circadian genes. The symbol  indicates degradation pathway. (Adapted from: Pudasaini et 
al. Biochemistry 2013, 52, 7150-7158)  
Although specific functions of ZTL and FKF1 are known, the function of LKP2 is still 
ambiguous. Notably, research has shown LKP2 is an important member of the ZTL family and 
plays a crucial role in maintaining circadian rhythm. Shultz et al. (2001) first identified LKP2 gene 
and have shown LKP2 functions either within or very close to the circadian oscillator in A. 
thaliana. In the study they found overexpression of LKP2 led to several arrhythmic phenotypes 
for the multiple circadian outputs both in constant dark and light34. Incidentally, the overexpressed 
mutant showed loss of photoperiodic flowering time and long hypocotyls. Moreover, another 
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independent study by Baudry et al. found that ztl fkf1 lkp2 triple mutant showed weaker circadian 
rhythm than the double mutant ztl fkf1 suggesting LKP2 participates in the circadian rhythm 
process12. Mechanistically, what differentiates LKP2 from the other members of the ZTL family 
is unknown.  
Herein, we investigated the thermal photocycle of Arabidopsis thaliana. We anticipate the 
kinetics study can provide important clues about the active site configuration that could possibly 
decipher the actual role of LKP2 in the plant circadian clock and what differentiates its function 
from ZTL and FKF1. Further, we will extend our research to study LKP2 protein of Brassica rapa, 
where due to gene duplication, roles of ZTL and FKF1 is undertaken by set of three LKP2.  
5.3.1 Arabidopsis thaliana LKP2    
 
The PAS domain of the LKP2 shares 77% amino acid sequence identity with Zeitlupe and 
67% identity with FKF134. The sequence alignment of proteins in ZTL family revealed, LKP2 
differs with other LOV proteins at the position 153, where both other members ZTL and FKF1 as 
well as all other characterized LOV proteins contain a conserved glutamine residue at this site. As 
discussed earlier in fig 41, a conserved glutamine flip plays an important role in LOV photocycle 




Figure 49: Sequence alignment of the ZTL family: Sequence alignment showed LKP2 differs 
from ZTL and FKF1 at the conserved glutamine (Q) position instead it has Leucine (L) 
In LKP2 the polar glutamine (Q) residue is replaced by a hydrophobic leucine (L) residue. 
Importantly, same substitution abrogates function in all other LOV domains. We therefore, 
concluded to introduce a point mutation in LKP2 (L153Q) to mutate the leucine residue to the 
glutamine observed in all other LOV domains. Presumably, the comparison of the kinetic 
photocycle of both wild type and mutant could help us delineating the signaling pathway of LKP2.  
5.3.2 Brassica rapa LKP2 
 
Sequence alignment of ZTL family proteins with the F-box harboring LOV domain 
proteins of Brassica rapa revealed only proteins with the sequence similarity to LKP2 and no 
copies of ZTL and FKF1. Incidentally, evolutionarily, B. rapa has undergone genome duplication 
resulting in complete loss of some of the gene and polyploidization of others. Interestingly, in 
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Brassica rapa, triplication of LKP2 is observed and it is believed that these additional copies have 
undertaken the role of ZTL and FKF136. Importantly, all three harbor the leucine at position 153, 
which should lead to inactive proteins. 
 
Hitherto plant circadian rhythm studies have been done in A. thalaina which had been a 
model organism for the circadian rhythm research. We extended our research and studied thermal 
kinetics study of all three LKP2 present in B.rapa termed as BrLKP2-A, BrLKP2-B and BrLKP2-
C. Sincere thanks to Shital Kale and Shannon Swisher for providing the BrLKP2-C data. The data 
reported in Shital Kale’s thesis used wrong temperature values.  
5.4 Results and discussions  
Reversion of the light state (C4a adduct state) to the dark state (oxidized flavin) was 
monitored at time interval of 20 min for several days. The data was plotted between absorbance 
vs. time at different temperature ranging from 29-43 oC. Each data set was collected in triplicates. 
Figure 50: Sequence alignment of all three LOV domain harboring F-box proteins in 
Brassica rapa along with the LOV domain proteins of  the ZTL family. The sequence 
alingement clearly reveals all the  proteins are similar to LKP2 of the A thaliana. Like LKP2, 
Instead of conseved glutamine (Q) all the three proteins of B.rapa have leucine (L) 
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The half-life of the protein was calculated by the average of rate constant calculated after data 
fitting with an exponential decay equation.  
𝑦 = 𝐴1 ∗ exp :−
𝑥
𝑡1< + 𝑦0 
 
Figure 51: (A) The spectra of LKP2 protein exemplifies the C4a adduct formation. The dark state 
(black) at 450 nm with the shoulder peaks at 425 and 475 nm represents oxidized flavin. Blue light 
bleaching results in a light state peak (red) representing a C4a adduct formation. (B) Reversion of 
the light to the dark state demonstrate first order kinetics as shown by the absorbance band at 450 
nm (red) and 478 nm (black).  
To better understand the photocycle of the LKP2 and BrLKP2, Arrhenius and Eyring 
analysis of dark state recovery was performed and different kinetic parameters such as activation 
energy and entropy were calculated.  
5.4.1 Thermal kinetics of A. thaliana LKP2 
 
Thermal kinetics studies indicate that compared to other LOV domain proteins, LKP2 has 
slower adduct decay rate with the longer half-life (t) of 137 hr., while that of mutant is reduced to 
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7 hours. The observation clearly shows the importance of glutamine (Q) in the active site of the 
LOV domain proteins. Furthermore, the Eyring and Arrhenius analysis of LKP2 revealed strong 
temperature dependence of LKP2 owing to the higher enthalpy of activation (115.9 KJ/mol.). 
LKP2 mutant (L153Q), on the contrary showed less temperature dependence due to the low 
enthalpy of activation (99.4 KJ/mol.). Notably, the mutation has caused the enthalpy of activation 
similar to that of the fast-cycling LOV domain proteins (70-100 KJ/mol.)24.  
 
Figure 52: Thermal kinetics comparison of A. thaliana LKP2 and LKP2 (L153Q) mutant: 











5.4.2 Thermal kinetics of BrLKP2- B and C 
 
5.4.2a Thermal kinetics of BrLKP2 B 
 
The slow cycling BrLKP2-B has a half-life of 27 hours, while the half-life of the mutant is 
reduced approximately by 10-fold to 2.6 hours. BrLKP2 WT shows weak temperature dependence 
compared to AtLKP2, due to relatively low activation energy (87.14 KJ/mol. vs. 115.9 KJ/mol.) 
that is compensated by an unfavorable entropy (-58.7 J/K vs 31.1 J/K).  
The mutant with the half-life of 2.6 hours demonstrated activation energies within the range 
of fast cycling LOV proteins (70-100 KJ/mole). Moreover, Eyring analysis indicated the low 
enthalpy of activation is compensated by a large unfavorable entropy (-67.49 J/K) 
Kinetic Parameters Wild Type Mutant 
Activation Energy (Ea) (KJ/mol) 115.9 99.4 
Enthalpy (DH±) (KJ/mol) 113.3 96.9 
Entropy (DS±) (J/mol.K) 31.1 -3.8 
t  (25 oC) 136 hrs. 7 hrs. 




Figure 53: Thermal kinetics of BrLKP2-B and BrLKP2 (L149Q) mutant: A and C: 
Arrhenius and Eyring plot of BrLKP2-B (29-165). B and D Arrhenius and Eyring plot of the 
mutant L149Q mutant  






Kinetic Parameters Wild Type Mutant 
Activation Energy (Ea) (KJ/mol) 87.14 78.14 
Enthalpy (DH±) KJ/mole 84.57 75.56 
Entropy (DS±) J/mol.K -58.74 -67.49 
t (at 25 oC) 27 hours 
(measured) 
2.6 hours (calculated) 
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5.4.2b Thermal kinetics of BrLKP2 C  
 
The kinetics parameters of BrLKP2-C were similar to BrLKP2-B where the half-life of the wild 
type was 29 hours (vs. 27 hours of B-variant).  
The BrLKP2-C LàQ behaved similar to the mutant of the LàQ mutant of the B variant 
with a half-life of 2.5 hours (2.6 hours of B variant). However, the low enthalpy of activation of 
the BrLKP2-C mutant was compensated by relatively large unfavorable entropy of activation 
(144.22 J/K vs. -67.49 J/K). The data clearly revealed a far weaker temperature dependence, 
characteristic of a very low enthalpy of activation compensated by a large negative entropy of 
activation.  
 
Figure 54: Thermal kinetics of BrLKP2-C: A and C: Arrhenius and Eyring plot of BrLKP2-C 
(29-165). B and D Arrhenius and Eyring plot of the mutant (L149Q).  
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 Based on our studies, we propose LKP2 shows different temperature dependencies which 
may allow for temperature compensation, temperature sensing pathways as has been indicated for 
other photoreceptor families. Our results indicated At-LKP2 protein demonstrated higher 
temperature dependencies compared to both the variants of Br-LKP2 (B and C). Moreover, both 
the variants of BrLKP2 (B and C) showed nearly similar temperature dependencies. Notably, the 
life time of the adduct decay was longer in the At-LKP2 than Br-LKP2. Furthermore, our studies 
corroborate that the invariant glutamine in the LOV domain family is critical for functioning as 
significant difference was seen in the lifetime of the LKP2 photocycle when leucine (L) was 
mutated to glutamine (Q).  
5.5 Materials and methods 
Cloning and Protein Purification 
The nucleotide encoding LKP2 was obtained from The Arabidopsis Information Resource 
(Tair). N-terminal and C-terminal truncated LKP2 construct (16-165) was cloned by PCR 
amplification. The PCR products were examined using 1% agarose gel followed by the gel 
purification. The constructs were cloned into 6-His parallel vector with ampicillin resistance using 
















BamH1 and Hind III restriction sites. LKP2 (16-165) construct was further used to introduce a 
L153 Q point mutation using Quick change protocol (Stratagene). Both, LKP2 construct (16-165) 
and the mutant (L153Q) sequence were verified by DNA sequencing (Genewiz). Proteins were 
expressed in Escherichia coli BL.21(DE3) cells. Cells were grown at 37 °C until optical density 
(OD600) reached 0.5, at which the temperature was reduced to 18 °C for 30 min. The protein 
expression was induced by 0.2 mM isopropyl thiogalactoside (RPI). After 22 h, the cell pellets 
were harvested and stored in 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol at 4 °C. LKP2 
construct and mutant pellets were purified using Ni-NTA affinity resin (Qiagen) at 22 oC; Washing 
and elution of protein was done by 20 mM imidazole and 250 mM imidazole, respectively. His6 
affinity tag was cleaved by incubating the eluted protein with 2mg/ml TEV protease enzyme 
(Tobacco Etch Virus Protease) overnight. The residual imidazole and the His6-TEV was removed 
by buffer exchange followed by another round of affinity purification. The protein was further 
purified by size exclusion column (superdex S-200) already equilibrated with the 100 mM NaCl, 
50 mM Hepes (pH 8.0) 10 % glycerol buffer.  
Cloning and Protein Purification of BrLKP2 
The nucleotide encoding BrLKP2A, B and C were obtained from Jin A. Kim from the 
Rural Development Agency, Republic of South Korea. Both N and C-terminal were truncated 
BrLKP2 construct (29-165) was cloned by PCR amplification. The PCR products were examined 
using 1% agarose gel followed by the gel purification.  The constructs were cloned into GST 
parallel vector with ampicillin resistance using EcoR1 and Not1 restriction sites. A point mutation 
of L143Q was introduced using Quick change protocol (Stratagene). Both, the constructs BrLKP2-
B, C and their mutants (L153Q) sequence were verified by DNA sequencing (Genewiz). Proteins 
were expressed in Escherichia coli JM109 cell lines. Cells were grown at 37°C until optical density 
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(OD600) reached 0.5, at which the temperature was reduced to 18 °C for 30 min. The protein 
expression was induced by 0.2 mM isopropyl thiogalactoside (RPI). After 22 h, the cell pellets 
were harvested and stored in 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol at 4 °C.  
 BrLKP2 construct and mutant pellets were purified using glutathione affinity resin 
(Qiagen) at 22 oC. Washing was done by 100 mM NaCl, 50 mM Hepes (pH 8.0) 10 % glycerol. 
The GST tag was cleaved by incubating the eluted protein with 2 mg/mL TEV protease enzyme 
(Tobacco Etch Virus Protease) overnight. The cleaved protein was eluted in the buffer, another 
round of nickel-nitriloacetic acid chromatography was done to remove His6-TEV followed by a 
final purification with a superdex S-200 size exclusion chromatography.  
UV-Vis Absorbance Spectroscopy and Kinetics: 
UV−visible absorbance spectroscopy of LKP2 16-165 and LKP2 (L153Q) 16-165 were 
conducted either on Agilent 8453 spectrophotometer or BioTek plate reader. Spectra for thermal 
reversion was recorded at the concentrations of 50 µM. All kinetics experiments were performed 
by illuminating the protein samples with a flood light source (150 W), while incubating the protein 
on ice to populate the light state. Each data set were done in triplicates to check the consistency in 
the data collection. After illumination of the dark state protein, spectra were recorded at different 
times until the absorbance reached to the saturation state. Thermal reversion kinetics of LKP2 and 
BrLKP2 constructs were obtained at the absorbance of 450 nm and 478 nm with respect to time.  
Data fitting was done using mono- and bi-exponential equations as required to extract 
kinetic parameters. All time constants were reported as 1/ k adduct scission that was averaged 
between the values obtained at 450 and 478 nm. All other kinetics parameters were calculated 
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CRYSTAL STRUCTURE OF CRYTOCHROME LIKE ALGAL PROTEIN: OTCPF1 
 
A1. Introduction 
Light is the prime source of energy in all forms of life ranging from the simplest organisms 
like photosynthetic algae to the mammals. Algae are the supreme producer of the biomass on the 
Earth and contribute significantly to the global production and biogeochemical cycling. Just like 
plants, photosynthetic algae utilize light for the growth and development processes. Light dictates 
essential physiological process in algae such as photosynthesis, gene expression, and circadian 
clock entrainment. Recently, several algal genome sequences including diatoms and green algae 
(such as Ostrococcus tauri and Chlamydomonas reinhardtii) were made available. Interestingly, 
photoreceptors such as red and blue light photoreceptors including cryptochromes and photolyase 
type of photoreceptors were found. Phylogenetic analysis of Ostrococcus tauri revealed 5 genes 
belonging to cryptochrome photolyase family (CPF) family.  
The cryptochrome photolyase family1 (CPF1) family consist of the proteins of varied 
functions. The family consists of three major groups of the proteins: the CPD (cyclobutane 
pyrimidine dimer) photolyase, (6-4) photolyases and the cryptochrome. While both CPD
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photolyase and (6-4) photolyases participate in ultraviolet-induced DNA repair activity, the 
cryptochrome does not participate in the DNA repair activity. The cryptochrome acts as a 
photoreceptor protein in plants and insects, whereas in animals it works in a light-independent 
manner and is a part of the core circadian clock. Interestingly an algal protein OtCPf1 has been 
found to possess dual functionality; not only it showed the (6-4)-photolyase activity but also 
interacted with CLOCK and BMAL1 characteristic of the mammalian circadian clock.  
We particularly became interested in studying the otcpf1 as it possesses the characteristic 
of the mammalian cryptochromes. Since photosynthetic alga show robust circadian rhythm and 
alga being a unicellular or simplest cell to study the function and signaling mechanism of the 
critical circadian proteins can easily be understood.  
A1.2 Protein Crystallization 
 
To obtain better insights of the cryptochrome and its signaling mechanism, we crystalized 
deletion mutant of OtCPf1 (D 258-293). We deleted the disordered loop from the otcpf1 full length, 
to facilitate the protein to crystalize. Hanging drop method was used to crystalize the protein after 
purification in the reduced environment in the presence of DTT (1,4-Dithiothreitol).  
Initially, protein screening was done at the room temperature in the dark room using 
Hampton crystal screens. However, multitude of nucleation centers were formed and as a result 
the crystals appeared were not big enough to give a conclusive data after X-ray crystallography. 
All our efforts to avoid getting multiple nucleation centers such as changing pH of the buffer, 
reducing the precipitant or the protein concentration did not yield better results. Delightfully, 
purification and crystallization procedures done at the lower temperature (4 oC) was able to reduce 
the number of nucleation centers in each well yielding two or three crystals per well. X-ray 
 
 171 
crystallography study of the crystals provided us 2.9 Å of data set, which we are in the process of 
solving.   
A2 Results and discussion 
 Currently, the unfinished data has provided us some insights of the protein structure. The 
comparison of the OtCPf1 protein with the cryptochrome-2 revealed the presence of similar 
residues in the active site. Moreover, the residues which are essential for the KL001 binding at the 
active site (as discussed in chapter 2) are also present (Fig 46 C). We anticipate our success in 
crystallizing otcpf1 will open new avenues to study the drug binding in the cryptochrome binding 




Figure 55: Structure of OtCPf1 (A) The cartoon structure of OtCPF1 (B) FAD bound in the 
FAD binding pocket of OtCPF1. (C) Residues which were found to be essential for the KL001 
binding are present and labled. (D) Side chain of the FAD snuggle close to the tryptophan and 




A3 Future direction.  
As OtCPf1 has a structural similarity with the mammalian cryptochrome, therefore, we 
plan to crystallize the protein with one of the drugs from the ZL library and get the crystal structure 
to study the structure-activity relationship. In addition, we plan to use the Otcpf1 protein for 
determining the binding efficiency of the small molecules.  
A4 Materials and methods 
A4.1 Cloning and Protein Purification  
The codon optimized full length Otcpf1 were cloned into pGST parallel vector. The 
sequence was verified by DNA sequencing (Genewiz). Cells were grown in Luria-Bertani (LB) 
medium at 37 oC, until the OD600 reached to 0.5. The temperature of cells was decreased to 18oC 
for 45 min. Protein expression was induced by 0.2 mM of isopropyl thiogalactoside (IPTG). Cell 
harvesting was done after 22 hours; cells were pelleted and were stored in 50 mM Tris (pH = 7.4), 
100 mM NaCl and 10% glycerol.  
OtCPf1 was purified with glutathione affinity resin (Qiagen) at 4 oC. Bound protein 
OtCPf1-GST in column was treated with 2 mg of TEV protease per milliliter of resin overnight at 
4 oC. 20 mM of Imidazole was added to the eluted protein; an additional round of Ni-NTA 
chromatography then cleaved His6-TEV. Protein was then incubated with 5 mM Dithiothreitol for 
30 min at 25 oC to avoid oligomerization. The size Exclusion Chromatography was then used to 
further purify protein using 50 mM Tris (pH = 7.4), 100 mM NaCl and 10% glycerol. Crystal tray 





Structural Analysis:  
Initially, OtCPf1 deletion mutant crystals were obtained with the reservoir solution 
containing 0.1 M HEPES sodium (pH=7.5) 1.4 M sodium citrate tribasic dihydrate in dark at room 
temperature at the 6 mg/mL and 9 mg/mL concentration. Crystals were also obtained at 4 oC with 
the reservoir solution of 1.6 M Sodium citrate tribasic dihydrate pH 6.5 (Hampton screen in HR2-
112) 
Diffraction data were collected at the F1 beamline at the Cornell energy synchrotron source 
(CHESS). Data was collected with 20% ethylene glycol as a cryoprotectant. The diffraction data 
obtained were scaled and reduced in HKL2000. The phase information was obtained by molecular 
replacement with phaser and phenix and a search model of photolyase (Protein Data Bank code 
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SCANNED 1H AND 13C NMR SPECTRA 
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